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ABSTRACT 
The rising use of natural products creates an imperative need for an enhanced 
awareness of the safety of current and new products making their way into the 
marketplace. An important example is natural products containing lignans as the 
principal active component. Despite their structural similarity the lignan of creosote 
bush can cause hepato- and renal toxicity while the lignans of flaxseed have no reported 
serious toxicity. This dissertation aimed to investigate the oxidative metabolism of such 
lignans to determine whether reversible, competitive interactions and/or bioactivation 
may explain the differences in their apparent toxicity.   
The first objective was to study the metabolism and bioactivation of 
nordihydroguaiaretic acid (creosote bush) and secoisolariciresinol (flaxseed).  
Nordihydroguaiaretic acid metabolism in rat liver microsomes led to the production of 
three glutathione adducts formed via ortho-quinone reactive intermediates.  This 
metabolism was independent of NADPH and thus attributed to autoxidation.  
Secoisolariciresinol metabolism yielded lariciresinol and no glutathione adducts 
suggesting an absence of bioactivation to reactive quinone intermediates. 
The second objective was to study the autoxidation of nordihydroguaiaretic acid.  
The major autoxidation product was a unique, stable schisandrin-like cyclolignan which 
was the result of nordihydroguaiaretic acid cyclization.  The half-life of 
nordihydroguaiaretic acid in aqueous solution, pH 7.4, 37ºC is 3.14 hours suggesting the 
cyclolignan may be responsible for some of the biological effects of 
nordihydroguaiaretic acid. 
The third objective was to study the inhibition of cytochrome P450 isoforms 
1A2, 2B, 2C11 and 3A by lignans derived from creosote bush and flaxseed.  None of the 
lignans caused irreversible inhibition.  Both creosote bush and flaxseed lignans caused 
reversible inhibition of P450 enzyme activity that involved competitive or mixed-type 
inhibition, however the inhibition was present at nonphysiologically relevant 
concentrations.  Activation of cytochrome P450 isoforms was also observed at low 
 ii
lignan concentrations. The results suggest that P450-mediated bioactivation or reversible 
inhibition cannot explain the differences in toxicity noted between the lignans of 
creosote bush and flaxseed. 
This work suggests a minimal risk for drug-lignan interactions at P450 enzymes. 
Further studies are warranted to determine the presence and biological and toxicological 
role of the nordihydroguaiaretic acid cyclolignan in herbal preparations. 
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1. LITERATURE REVIEW 
 
Concerns are being raised by the general public about the extensive use of 
pharmaceuticals at the present time.  The public scepticism of taking “chemicals” to 
treat their illnesses has led to an increased interest in the use of herbal preparations and 
natural products as an alternative to prescription medications as well as over the counter 
products.  The substantial increase in the natural products available on the shelves of 
pharmacies, health food stores, grocery stores and via the internet has given consumers 
alternatives for self-treatment of ailments ranging from colds to joint pain to depression.  
The enhanced availability and use of such products follows from a public expectation of 
greater safety (with similar efficacy) associated with “medications” from “natural” 
sources. 
Many natural products on the market today have their origins in ancient and 
traditional medicines which were used in countries all around the world.  One example 
of a traditional medicine with origins in North America is the creosote bush which is 
native to the southwestern United States and Mexico.  The creosote bush has been used 
traditionally by aboriginal peoples for centuries.  Since benefits were found from using 
the creosote bush in traditional healing, an extract of the plant has now been formulated 
into a capsule which can be purchased under the name of Chaparral. 
Traditional use of the creosote bush by aboriginal peoples for centuries suggests 
that the creosote bush is an effective natural medicine.  While traditional creosote bush 
use appears to be quite safe, chronic use of Chaparral leads to toxicity.  The striking 
differences in the safety profiles of the two forms of the natural product should serve as 
a warning to demonstrate that when used out of their proper context, natural products 
have the same potential for toxicity as pharmaceuticals.   
The active ingredient in creosote bush which is believed to be responsible for 
both the efficacious and toxic properties is the lignan, nordihydroguaiaretic acid 
(NDGA).  Lignans are a class of compounds found in many plants such as creosote 
bush, flaxseed, sesame seeds, sunflower seeds, soy beans, garlic and dried fruits1.  
Flaxseed is the highest source of the lignan, secoisolariciresinol diglucoside (SDG).  
SDG and NDGA show close structural similarities, which is an important observation 
because we see no toxicity associated with flaxseed use. 
Flaxseed use is increasing in popularity both as an added ingredient to breads and 
nutritional snacks as well as a natural product.  Lignans are being extracted and 
concentrated from flaxseed and sold in capsule (Brevail™) or powder form (Beneflax).  
In addition to being associated with safety, flaxseed has demonstrated positive effects 
and is being considered as beneficial for cardiovascular and anti-cancer health. 
In this delicate balance, the active lignan component of flaxseed can cause 
positive biological effects while on the other side the lignan from Chaparral causes 
negative biological effects.  There are only slight variations in the chemical structures of 
flaxseed and chaparral lignans although they are enough to ultimately tip the balance 
from safety to toxicity. 
My dissertation aims to investigate why the lignan in Chaparral is associated 
with toxicity while the lignans from flaxseed have limited reported toxicity.  My 
research will specifically focus on attempting to explain the differences in the putative 
lignan toxicity by determining whether oxidative metabolism of the lignans can lead to 
bioactivation or cytochrome P450 (450) inhibition and if so, whether bioactivation is 
mediated through P450 enzyme processes.  Furthermore, my research will investigate 
the possibility of toxicity arising from lignan-mediated inhibition of P450 metabolism 
either through mechanism-based or reversible inhibition mechanisms.  Critically looking 
at how changes in lignan structure can affect metabolic fate will provide useful 
information for making predictions about the safety of natural products containing 
lignans as the principal bioactive components.  Natural product wellness and therapeutic 
value will only be satisfactorily realized with more safety (and efficacy) data. In these 
terms, my dissertation research will help to fill a significant void in our knowledge of 
lignan safety. 
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My dissertation is set up as a paper based format containing three papers which 
make up chapters four to six of this thesis.  Two of the papers have been previously 
published and the third has been submitted for publication.   
 
1.1 Natural Health Products 
The Natural Health Products Directorate (NHPD), a division of Health Canada, 
defines natural health products (NHP) as vitamins and minerals, herbal remedies, 
homeopathic medicines, traditional medicines such as traditional Chinese medicines, 
probiotics, and other products like amino acids and essential fatty acids2.  Consumers are 
able to purchase NHP over the counter, without a prescription.  The NHP should be both 
safe and efficacious with customers having the security to self-medicate to treat or 
prevent disease.  
 
1.1.1 Functional Foods and Nutraceuticals 
Health Canada identifies a functional food as being similar in appearance to, or 
may be a conventional food that is consumed as part of a usual diet, and is demonstrated 
to have physiological benefits and/or reduce the risk of chronic disease beyond basic 
nutritional functions, i.e. they contain bioactive compound3.  An example of a functional 
food is carrots, which contain beta-carotene that acts as an antioxidant to neutralize free 
radicals, which can cause damage to cells4.  Wheat bran is another functional food that 
can reduce the risk of breast or colorectal cancer due to the insoluble fibre present5,6. 
According to the Agriculture and Agri-Food Canada website, a nutraceutical is a 
product isolated or purified from foods that is generally sold in medicinal forms not 
usually associated with foods. A nutraceutical is demonstrated to have a physiological 
benefit or provide protection against chronic disease3.  Examples of nutraceuticals are 
lycopene, from tomatoes, used to reduce the risk of prostate cancer7 and lutein, from 
green vegetables used to reduce the risk of macular degeneration8.  Nutraceuticals are 
considered to be NHP.   
Dr. Stephen L. DeFelice, the founder of the Foundation for Innovation in 
Medicine (FIM), created the term nutraceutical in 1989 as a comprehensive term which 
includes foods, dietary supplements (as defined in Dietary Supplementation Health and 
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Education Act) and medical foods that have a health-medical benefit including the 
prevention and/or treatment of disease9.   
 
1.1.2 Regulation of Natural Health Products 
Natural health products are regulated in Canada through the NHPD.  Starting in 
January 2004 all NHPs had to comply with the regulations set out by the NHPD10.  In 
January 2007, the NHPD published the new natural health products compliance guide to 
set a precedent for regulatory agencies and industry for ensuring the safety of NHP10.  
The compliance guide outlines a risk based approach followed by an action plan for all 
NHPs that are not authorized for sale in Canada. 
Approval for licensing of a NHP requires that the product meet a series of 
guidelines, not unlike those set out for a pharmaceutical agent.  An overview of these 
guidelines can be found at http://www.hc-sc.gc.ca/dhp-
mps/prodnatur/legislation/docs/index-eng.php11. In brief these requirements include: 
product number, dosage form, recommended dose and route of administration, 
recommended use, duration of use and the quantity of medicinal ingredient of the natural 
product12. A Drug Identification Number (DIN) or a Natural Product Number (NPN) or 
DIN-HM, indicates that a NHP has been assessed for quality, safety and efficacy by 
Health Canada13.  Other requirements such as adverse reaction reporting are also under 
the auspices of the NHPD.  
1.1.3 Benefits versus Risks of Natural Products 
One major area of concern for NHP use is the issue of potential benefits versus 
risks to health.  NHP-drug interactions are possible and may be as common as drug-drug 
interactions.  Since consumers can purchase NHP over the counter without having to 
speak directly to a pharmacist there is an increased risk of NHP-drug interactions.  In 
addition a lapse in communication with physicians, whether they do not ask about 
concurrent herbal use or the patient does not relay herbals use to the physician, can 
potentially result in unfavourable consequences. 
The potential benefits of St. John’s Wort as an antidepressant for the treatment of 
mild to moderate depression have been documented14 however safety issues exist related 
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to interactions with other drugs due to induction of cytochrome P450 (CYP3A4 and 
CYP2C9)15 and P-glycoprotein by preparations with high hyperforin content16.  In the 
case of concurrent warfarin use, the induction of CYP2C9 mediated through St. John’s 
Wort can reduce anticoagulant effects by decreasing serum levels of warfarin17 which 
would lead to an increased risk of blood clots18.  However, some reports claim that since 
herbals such as St. John’s Wort do not affect platelet function, that they do not pose a 
risk for increased risk of bleeding in post-surgical patients19.  
Drug interactions resulting from inhibition of CYP3A activity by bergamottins in 
grapefruit juice20 and CYP3A4 and 2C9 inhibition by ginsenoside metabolites from 
ginseng preparations have also been observed21.  There are mixed reports in the 
literature however, claiming that asian ginseng can interfere with blood clotting by 
inhibiting platelet activating factor17, which conflict studies that report that ginseng does 
not appear to affect blood clotting19. 
The active ingredient of the increasingly popular herbal remedy COLD-fX® is an 
extract containing greater than 80% of polysaccarides from Panax quinquefolis, North 
American ginseng root22.  The makers of COLD-fX® warn that those individuals who 
use warfarin should avoid concurrent use of their product as drug interactions will 
occur22.   
To make matters confusing for the public taking their product, the additional 
safety information relating to COLD-fX® states that “In clinical trials and from post-
marketing surveillance, COLD-fX has been shown safe and well-tolerated. No known 
interactions have been found with medications, diseases, or other herbal products. 
However, as specific clinical trials have not been conducted to investigate these 
interaction potentials, it is advised that individuals with serious medical conditions or 
those taking medications consult a health care practitioner prior to use.”22.  The 
confusion arises when in one breath the manufacturer is telling the consumer that there 
are no known interactions yet that they should not be taking the product with warfarin 
medication.   
Nonetheless it is important that the makers of COLD-fX® are recommending that 
consumers consult with their health care providers before use of the NHP.  
Appropriately labelled NHPs should serve as warnings to consumers that the product 
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can have the same potential for interactions as concurrent drug therapies might.  It is 
also imperative that health care practitioners, albeit physicians, pharmacists or dentists17 
have  complete and thorough background on their patients which would include 
information about concurrent herbal use. 
 
1.2 Lignans from Creosote Bush and Flaxseed 
Lignans are cinnamic acid derivatives that are synthesized from the amino acid 
phenylalanine via the phenylpropanoid pathway in plants23.   Lignans are dimers of two 
C6C3 units linked through the β and β' carbons23.   The basic skeleton structure of a 
lignan is shown in Figure 1.1.  Various substituents can be added at both the aromatic 
and aliphatic regions of the molecule which will give the lignan different physical and 
chemical properties. 
 
γ
β
α6
5
4
3
2
1
C6C3 Lignan subunit
Lignan Skeleton  
Figure 1.1: Structures of the basic lignan subunit and the general lignan skeleton. 
  
1.2.1 Creosote Bush Background 
Larrea tridentata, commonly known as the creosote bush or Chaparral, is a shrub 
native to the deserts of the southwestern United States and Northern Mexico.  Creosote 
bush is an ancient shrub estimated to have originated in North America 8.4 to 4.2 million 
years ago24.  The catechol lignan, nordihydroguaiaretic acid (NDGA), makes up about 
3.8% dry weight of the creosote bush and is believed to be an active component25.  As it 
is a polyphenolic catechol, NDGA has lipophilic characteristics (Figure 1.2). 
Nordihydroguaiaretic acid occurs as the meso form in the creosote bush and is a solid at 
room temperature (mp 185-186). NDGA is found in highest concentrations in the leaves 
(38.3 mg/g) and green stems (32.5 mg/g) with smaller concentrations found in the 
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flowers and stems (<5 mm)25.  In addition to varying concentrations within the creosote 
bush, NDGA content may vary with respect to geographical location and season26.  
Being a secondary plant metabolite, it is likely that NDGA serves to protect the creosote 
bush from herbivorous predators27.  The lambda-max for NDGA is 282 nm, which could 
infer protection against UV-radiation. 
HO
HO
OH
OH  
Figure 1.2: Structure of nordihydroguaiaretic acid 
 
1.2.1.1 Historical uses of Creosote Bush 
Due to its lengthy history, the creosote bush has been used by various peoples 
including Mexicans and Native American peoples, including the Pima Bajo, Seri and 
Tohono O’odham28.   Traditional use of the creosote bush by Native Americans includes 
treatment of ailments such as arthritis, cancer, tuberculosis and rheumatism29.  The 
Tohono O’odham make a tea from the leaves and stems of the creosote bush to drink 
after long spiritual walks to help ease aching muscles (author’s personal communication 
with Terrol Dew Johnson).  Creosote bush leaves and stems can also be boiled and then 
reduced down to an oil which is combined with Vaseline, to be used as an ointment for 
diaper rash or HIV lesions.  Branches from the creosote bush are burned during rituals 
and funeral rites. 
Due to its lipophilic structure and antioxidant properties as a result of its 
polyphenolic groups, NDGA was used as a food additive for fats and oils30.  Studies 
performed in 1968 by the Canadian Food and Drug Directorate using a rat model for 
toxicity found that NDGA caused cystic nephrotoxicity, leading to the banning of 
NDGA as a food preservative31. 
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1.2.1.2 Present uses of Creosote Bush 
Nordihydroguaiaretic acid can be purchased in the form of an herbal tablet called 
Chaparral, which is prepared from the leaves of the creosote bush.  Numerous examples 
document that the chronic use of Chaparral tablets has led to hepatotoxicity32-35.  The 
Canadian Food Inspection Agency issued a warning in 2005 stating that Chaparral sold 
as food in bulk and in any size package under any brand should not be consumed due to 
risk of liver and kidney problems36.  Chaparral is not currently available in Canada; 
however tablets can be purchased over the internet from various sources in the USA 
(author’s personal observations). 
There are many online websites that tout the use of Chaparral.  One site which 
sells Chaparral claims “The plant is known to act against free radicals and thus may be 
effective in preventing degenerative disease associated with aging.  This plant is of 
particular interest to us in cleansing the lymph system, an important part of 
rejuvenation.  It is anti-inflammatory and non-toxic.  Chaparral is a strong antioxidant, 
pain-killer and antiseptic.”37. The fact that the authors claim that Chaparral is non-toxic 
is contrary to scientific findings and could potentially be detrimental to unsuspecting or 
unquestioning consumers.  Other websites claim that Chaparral can be used to detoxify 
the body from industrial chemicals, has blood purifying properties and that it is anti-
bacterial and anti-fungal38. 
Some online sources do suggest using caution when taking Chaparral although 
the caution is to varying degrees.  An example is seen with Rose Mountain Herbs, where 
they warn that at one point Chaparral was banned by the American Herbal Products 
Association due to issues relating to hepatitis.  Therefore they advise that consumers 
should watch out for detrimental symptoms39.  Yet another site advises potential users of 
Chaparral that there have been negative liver effects seen with use; however, that the 
studies were perhaps flawed and that the blame was irresponsibly placed on Chaparral 
and not the other medications that were being concurrently taken40.  The aforementioned 
website was written with an air of self-righteousness but does, perhaps unintentionally, 
allude to the fact that there is the potential for herb-drug interactions. 
Arteaga et al27 recently reviewed the literature and found many traditional 
medicinal uses of the creosote bush.  Some examples, from a list of over 30 uses, 
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included treatment of acne, psoriasis, allergic problems, anemia, bronchitis, burns, 
cramping, menstrual pains, kidney pain and cystitis, sterility ulcer and weight loss.  
Despite these various pharmacological claims adequate in vivo results are lacking.  
The pharmacological properties of NDGA with respect to benefits related to 
cancer chemoprevention, cancer therapy, antimicrobial, fertility and hypoglycaemic 
effects, both in vitro studies and in vivo animal studies and human clinical trials, have 
been reviewed by Lambert et al41.   
Today NDGA and methylated analogues of NDGA are being studied for 
potential use as anti-viral agents against human immunodeficiency virus42, herpes 
simplex virus43, and growth inhibition of various tumours44-46.  Methylated analogues of 
NDGA are being investigated to reduce the toxicity that has been associated with 
NDGA.  
An NDGA formulation called Actinex® (Chemex Pharmaceuticals, Denver, CO), 
developed for the topical treatment of actinic keratoses, was approved by the FDA. 
However Actinex® was withdrawn from the market once it was established that it caused 
skin hypersensitivity47.  The skin hypersensitivity of NDGA and possible antimicrobial 
properties have resulted in the topical use of NDGA in the treatment of warts48.  NDGA 
has also been proposed for the treatment of corns, calluses and warts (US Patent 
5702694).  In addition, NDGA can be found in commercially available formulations for 
the treatment of acne and muscle aches, such as the LaKOTA™ joint care system, which 
lists Chaparral among the ingredients. 
 
1.2.2 Flaxseed Background 
Linum usitatissimum, commonly known as flaxseed, is an ancient crop first 
cultivated in 3000 BC and now grown worldwide.  Flaxseed is an important crop with 
40% of the world’s total production grown in Canada and 85% of Canada’s total crop 
grown in Saskatchewan49.  The flax plant has small blue flowers that eventually fall off 
the plant and yield a small pod containing small, flat, oval brown flaxseeds49.  According 
to the Flax Council of Canada, flaxseed’s many uses include human and animal 
consumption, processing into Linseed oil to be used for wood protection and as a 
strengthener for concrete and the production of Linoleum50.  Flaxseed contains 41% fat, 
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28% dietary fiber, and 21% protein by weight and is a rich source of the essential 
omega-3 fatty acid, alpha-linolenic acid49.  Flaxseed is a functional food which can be 
consumed in its whole form, ground or as an oil. 
 
1.2.2.1 Flaxseed Lignans 
Flaxseed contains a number of lignans which are similar in structure to NDGA.  
Like NDGA, the lignans in flaxseed may serve to protect the plant against herbivores51.  
The principle flaxseed lignan is secoisolariciresinol diglucoside (SDG), which is present 
as a 3-hydroxy-3-methylglutaryl (HMG) – SDG polymer in the plant52.  Detectable 
levels of matairesinol (MAT), the oxidized lactone analogue of SECO, can be also be 
found in flaxseed53. MAT may also be formed via oxidation of SECO in vivo as will be 
discussed in section 1.2.2.2.  A known by-product of isolation of SECO from flaxseed-
derived SDG is the hydrolysis product anhydrosecoisolariciresinol (ASECO), which will 
be further discussed in section 1.2.2.2.2.   
 
1.2.2.2 Metabolism of Flaxseed Lignans 
The metabolism of flaxseed lignans is summarized in Figure 1.3 below.  The two 
glucose moieties of SDG can be cleaved by β-glucosidase and β-glucuronidase enzymes 
in the intestinal microflora to form the aglycone SECO54.  Secoisolariciresinol can then 
be converted to MAT, lariciresinol and the mammalian lignans, enterodiol (ED) and 
enterolactone (EL)55,56.   Secoisolariciresinol conversion to MAT takes place in the large 
intestine and is the result of closure of the aliphatic hydroxyl groups to a lactone 
ring56,57.  Intestinal microflora also directly convert SECO to the mammalian lignans, 
ED and EL56.  Enterodiol may be oxidized to EL by the microflora in an analogous 
manner to how SECO is converted to MAT57.  Alternatively, EL may be produced from 
MAT55.   
In addition to intestinal metabolism, SECO and MAT are also oxidized in the 
liver by cytochrome P450 (P450) enzymes, however P450 metabolism is only a minor 
pathway for lignan elimination58.  SECO is converted to lariciresinol, isolariciresinol, 
two hydroxylated aliphatic metabolites and three aromatic hydroxylated metabolites in 
rat liver microsomes (RLM)58.  It should be noted however that the formation of 
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isolariciresinol may be due to acidic concentration of lariciresinol and may therefore be 
an analytical artefact.  Matairesinol was converted by RLM to a number of hydroxylated 
metabolites, both aliphatic and aromatic, in addition to demethylated metabolites58. 
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Figure 1.3: Flaxseed lignan metabolism of secoisolariciresinol diglucoside (SDG) to 
secoisolariciresinol (SECO), matairesinol, lariciresinol and the mammalian lignans 
enterodiol and enterolactone 
 
 11
1.2.2.2.1 Secoisolariciresinol 
Secoisolariciresinol is of importance to investigate as it is the major lignan found 
in flaxseed as part of the diglucoside complex SDG59.  The form of SECO found in the 
plant is (R, R)53 and it is a yellow solid at room temp (mp 114ºC)60.  The lambda max 
for SECO is 280 nm, which is very similar to that of NDGA (282 nm).  While NDGA is 
a catechol, SECO varies slightly in that it is a phenolic compound.  The presence of the 
aliphatic hydroxyl groups on SECO make it more water soluble than NDGA. 
 
1.2.2.2.2 Anhydrosecoisolariciresinol 
Anhydrosecoisolariciresinol shown in Figure 1.4, is also referred to in the 
literature as Shonanin61.  Several reports state that ASECO can be found in flaxseed61,62, 
although the actual presence of ASECO in the plant is disputed as the process to 
hydrolyze flaxseed for analysis also converts SECO to ASECO61.  Acid hydrolysis of 
SECO will result in the loss of a water molecule and the cyclization of the aliphatic 
moieties to form a tetrahydrofuran ring.  It should be noted that the furan ring of ASECO 
is distinct from the more hydrophilic lactone ring of MAT. 
Although it is still unclear as to whether or not ASECO is actually found in 
flaxseed, we have chosen to investigate it for the purposes of this dissertation.  Firstly, 
we believe that it is possible that oral ingestion of SECO could lead to the formation of 
ASECO in the acidic stomach environment.  Secondly, the structure of ASECO is 
intermediate to that of SECO and NDGA.  ASECO is similar to SECO in the aromatic 
regions but is missing the aliphatic hydroxyl groups, whereas the chain portion of 
ASECO is more similar to NDGA. 
O
H3CO
HO
OCH3
OH  
Figure 1.4: Structure of anhydrosecoisolariciresinol 
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1.2.2.2.3 Mammalian Lignans Enterodiol and Enterolactone 
The mammalian lignans enterodiol (ED) and enterolactone (EL) are products of 
the microbial metabolism of plant lignans and have been observed in human plasma and 
urine63.  Enterodiol and EL are derived from numerous lignans including SECO55, 
sesamin64, matairesinol, 7-hydroxymatairesinol, pinoresinol, isolariciresinol, and 
lariciresinol 65.  Numerous epidemiological studies have investigated the relationship 
between ED/EL and disease states.  Serum EL levels were inversely correlated to acute 
coronary events28 and breast cancer risk66,67, and plasma EL levels were inversely related 
to F(2) isoprostane levels, a marker of in vivo lipid peroxidation68.  However studies on 
prostate cancer risk69 and a subsequent study on serum EL and breast cancer risk70 have 
shown no relationship. Studies performed in vitro have demonstrated that ED and EL 
inhibit the growth of four estrogen-independent colon-tumour cell lines 71 and three 
human prostate cancer cell lines72, inhibit aromatase activity73and increase growth of 
MCF-7 and T47D human breast cancer cell lines74.  Enterodiol and EL have also been 
determined to be antioxidants in vitro75-77. 
Enterodiol and EL undergo hepatic metabolism to glucuronide conjugates in 
rhesus monkeys78 and by cytochrome P450 to a mixture of hydroxylated metabolites in 
hepatic microsomes from rat, pig and human 79; these metabolites have been found in 
urine from humans80, rats81 and rhesus monkeys78.  Jacobs and Metzler79 studied ED and 
EL metabolism in human, pig and rat liver microsomes and determined that both 
enterolignans undergo hydroxylation at various aliphatic and aromatic positions in 
mammalian microsomes, however they found that in uninduced microsomes, aliphatic 
hydroxylation predominated over aromatic.  Further investigations of enterolignan 
metabolites in human urine samples yielded aromatic hydroxylation products but not 
aliphatic hydroxylation metabolites80. 
 
1.2.2.3 Present uses of Flaxseed 
Flaxseed and the defatted flaxseed polymer are under study for the treatment of a 
number of disease states including hypercholesterolemia, diabetes and benign prostatic 
hyperplasia. Flaxseed has been shown to decrease cholesterol in animal models 
including rats82 and rabbits83 and flaxseed reduced LDL and total cholesterol in post-
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menopausal women 84,85. Studies on chronic flaxseed consumption in healthy humans 
however found no change in cholesterol 86. Defatted flaxseed polymer decreased 
cholesterol in rabbits87 and humans88.  Flaxseed improved glucose tolerance in humans89 
and flaxseed lignan complex improved glycemic control in type 2 diabetes patients90.  
Decreased prostate-specific antigen levels and proliferation rates were seen in benign 
prostatic hyperplasia patients treated with flaxseed91. Flaxseed was also shown to 
increase gamma-glutamyltranspeptidase in rats suggesting a potential hepatoprotective 
effect92-94. 
Fairly new to the market is the flaxseed product, Brevail®, which is being 
advertised for its benefits for breast health95.  Brevail® is composed of defatted flaxseed 
which provides up to a 35% increase in lignan content as opposed to consuming flaxseed 
alone.  The Brevail® website educates the general public by explaining that their 
product contains lignans which are natural plant compounds which would be a part of a 
vegetarian or plant based diet and claims that a vegetarian diet would provide small 
amounts of lignan to the body whereas Brevail® is a concentrated form of lignan and if 
taken on a regular basis it would provide an exact dose of lignan, much like a 
pharmaceutical product95.  Brevail® describes the lignan in their product (SDG) as 
having a chemical structure which is very similar to estrogen and thus it can 
competitively block excess estrogen for binding to the estrogen-binding receptor, 
allowing the body to eliminate the excess estrogen, thus improving breast health.  The 
website claims “excessive or “bad” forms of estrogen that are left unchecked may have 
adverse effects in the body” 95. 
 
1.3 Lignan Toxicology 
1.3.1 Nordihydroguaiaretic Acid Toxicity 
Although NDGA is now considered toxic, it was once utilized for its antioxidant 
properties30,96,97 as a food preservative in oil based products beginning as early as 
194830.  Studies confirming that NDGA caused nephrotoxicity in rats resulted in the 
removal of NDGA from the registry of compounds which have generally recognised as 
safe status31,98.  Feeding rats a diet of 0.5% or 1.0% NDGA resulted in cystic 
reticuloendotheliosis of the paracaecal lymph nodes and vacuolation of kidney 
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epithelium31.  ortho-quinone (o-Q) intermediates of NDGA were found in kidney 
extracts and in the lower one third of the ileum and caecum in rats fed a diet of 2% 
NDGA31, suggesting that an o-Q intermediate may be the cause of toxicity. 
The antioxidant properties of NDGA have demonstrated benefit in vivo in rat 
alveolar macrophages at a concentration of less than 10 µM99.  There appears to be a 
fine balance though as concentrations of NDGA from 20 to 100 µM caused prooxidant 
effects in clone-9 rat hepatocyte cultures100.   
The LD50 of NDGA in rats is 75 mg/kg and dosing causes a time and dose-
dependant increase in levels of serum alanine transferase, a marker for liver damage101.  
A potential mechanism suggested for liver damage was P450 inhibition.   
In rat epidermal and hepatic microsomes NDGA caused a concentration 
dependant inhibition of CYP1A2 and P450 enzymes affected by aryl hydrocarbon 
hydroxylase activities102.  The inhibition by NDGA manifested itself as type I binding 
difference spectrum102.  Type I binding difference spectrum refers to the interaction of 
the inhibitor with the heme portion of the P450 enzyme and results in a shift in iron(III) 
spin equilibrium from a low-spin to a high-spin which can have an effect on the redox 
state which thus affects the rate and extent of substrate turnover103.  This type of 
inhibition differs from a Type II binding spectrum which infers that the inhibitor binds 
to the heme portion of the P450 indicating an irreversible type of enzyme inhibition103.  
It is believed that the hydroxyl groups are important for the inhibition of P450102 as 
when the catechol was converted to an ortho-methoxy derivative, the inhibition 
ceased104.  NDGA has also demonstrated an ability to induce astroglial death by 
glutathione depletion105 which may be due to metabolism to reactive intermediates by 
P450. 
There are numerous case reports of Chaparral induced hepatotoxicity in 
humans32,33,35,106,107 which are believed to be due to NDGA as it comprises the majority 
of the dry weight of the creosote bush29.  The symptoms of NDGA toxicity ranged from 
nausea and anorexia32 to hepatomegaly and jaundice107 and hepatotoxicity was 
confirmed by liver biopsies.  Biopsies were consistent with injury caused by necrosis 
and periportal inflammation and bile duct proliferation33,35,107.  Symptoms began on 
average 3 months after beginning Chaparral treatment and subsided with cessation of 
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Chaparral use35,106.  If Chaparral use was reinitiated, the symptoms of hepatotoxicity 
returned. 
 
1.3.1.1 Apoptosis and Lipoxygenase Inhibition  
The toxic properties of NDGA are being utilized as a potential therapy for cancer 
treatment.  There are currently a variety of mechanisms reported as the means by which 
NDGA can induce apoptosis.  The mechanism of apoptosis is being studied by a number 
of groups in murine pro-B lymphocytes and has still not yet been fully elucidated, 
although it is believed to be triggered by a combination of factors such as glutathione 
depletion108,109, mitochondrial depolarization and oxidative processes109.  
In contrast to the above studies, NDGA has demonstrated anti-apoptotic activity 
in murine fibroblasts110.  Nordihydroguaiaretic acid blocked apoptosis by inhibiting 
tumour necrosis factor induced apoptosis by blocking caspase cleavage, mitochondrial 
inactivation, externalization of phosphatidylserine, 51Cr-release in addition to preventing 
intracellular calcium levels from increasing to allow phosphorylation of cytosolic 
phospholipase A2.   
Insulin-like growth factor 1 receptor (IGF-1R) is another target for apoptosis for 
which NDGA has demonstrated positive effects111-113.  NDGA inhibited the 
phosphorylation and activation of IGF-1R in breast cancer cells by inhibiting tyrosine 
kinase activity111.   
As NDGA has shown promise in a potential treatment for cancers, analogues of 
NDGA are also being examined.  While investigating NDGA inhibitory potency against 
IGF-1R kinase and an alternative target, 15-lipoxygenase (LOX), Blecha et al113 
determined that altering the structure of NDGA had a greater effect on the inhibition of 
LOX.  A cyclic form of NDGA resulted in similar inhibition of IGF-1R kinase as 
NDGA however the inhibition of LOX was 10-fold weaker, a promising result as LOX 
may play a role in suppressing tumours in breast cancer. 
Lipoxygenase enzymes are part of the arachidonic acid pathway which results in 
hydroxyeicosatetraenoic acids and leukotriene production.  Products of the lipoxygenase 
pathway have been associated with regulating apoptosis41,114.  Leukotrienes are 
connected with inflammation and its associated conditions such as pain and asthma.  
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Nordihydroguaiaretic acid is a known lipoxygenase inhibitor and has been used as a 
control compound in studies involving lipoxygenase inhibition115,116.  Part of NDGA’s 
ability to induce apoptosis is believed to be due to its ability to inhibit 
lipoxygenase115,117.  The lipoxygenase inhibiting properties have also been attributed to 
NDGA being an inhibitor of ovulation in rats118.  
 
1.3.1.2 Activation of Nordihydroguaiaretic Acid 
There are reports in the literature of NDGA undergoing activation in the 
presence of molecular oxygen.  Prevention of the oxidation of NDGA during extraction 
from plant sources is a major concern119.  Nordihydroguaiaretic acid can be activated in 
two distinct manners, one of which is activation to a quinone species31,120, which will be 
subsequently discussed in Section 1.3.3.   
The second method of NDGA activation is one which has been less studied.  
Wagner et al (1980) reported that an activated form of NDGA could interact with 
DNA121.  The authors noted that two hours after NDGA was dissolved in buffer, the λmax 
shifted from 280nm to 285nm to produce what was termed an “activated” NDGA which 
could bind with the major or minor grooves of DNA121.  If NDGA was left to sit in 
buffer alone, after 72 hours the clear solution changed colour to a red brown colour 
which absorbed at 460nm.  Interestingly Grice et al found that rats fed a diet enriched 
with NDGA had a red brown coloured material in lymph node cysts31, suggesting that 
perhaps they too had observed the formation of an “activated” NDGA.  It should be 
noted that the structure of the “activated” NDGA had not been identified by either 
researchers. 
 
1.3.2 Flaxseed Toxicity 
Flaxseed is a relatively safe natural product.  The small toxicity that is associated 
with flaxseed is due to the fibre content rather than the lignan content.  Fibre intake in 
excess of 60 to 70 g per day can cause dehydration and intestinal discomfort or gas122.  
The fibre of flaxseed contains cyanogenic glycosides which can release cyanide upon 
autolysis, however the levels of cyanide produced are below the limits which would be 
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toxic to humans123 and incorporation of flaxseed up to 28% in baked products have 
shown no harmful effects123,124. 
Kulling, et al125 studied SECO, MAT, ED and EL and concluded that all four 
lignans are devoid of genotoxicity after investigating their anueploidogenic, clastogenic 
and mutagenic potential.  No information is available on the genotoxic potential of the 
oxidative metabolites of the mammalian lignans125.   
Because of the estrogenic effects associated with flaxseed, gestational feeding 
studies have been performed to examine the effect of flaxseed in rats126,127.  Hemmings 
et al126 found that a 10% flax chow had no long-term effect on growth, development and 
behaviour.  Long term feeding studies on the rats showed that gamma-
glutamyltranspeptidase levels were increased in the livers after puberty with males 
showing a greater increase, 4-fold, in levels compared to females, 1.38-fold.  The 
authors state that the increase in the gamma-glutamyltranspeptidase levels however were 
not out of the ordinary when compared to changes that can occur in adult rats126.  Collins 
et al used higher levels of flaxseed in their studies, flaxseed added at 20 or 40% and also 
defatted flaxseed meal 13 or 26% of the total diet127.  Fetal development was not 
affected by the incorporation of flaxseed into the dam diet.  Whole flaxseed had no 
effect however defatted flaxseed delayed puberty in F1 males.  No differences in the age 
or weight at the time of onset of puberty was observed in female pups; however, both 
flaxseed diets caused irregular oestrus cycles in F1 females.  The levels of flaxseed 
studies were quite high though, levels which would not be consumed in humans. 
 
1.3.3 Formation of Quinone Species 
Quinones are reactive, electrophilic oxidants which are coloured compounds128 
and contain extended pi-conjugated systems. Based on their structure, the lignans 
NDGA and SECO may undergo oxidation to one or two types of chemically reactive 
quinone species, either an ortho-quinone (o-Q) or a para-quinone methide (p-QM).  
Documented evidence already exists of NDGA o-Q formation31,120.  Figure 1.5 shows 
the basic skeleton structures of the o-Q and the p-QM.  The two types of quinones will 
be presently discussed in sections 1.3.3.1 and 1.3.3.2.   
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Figure 1.5: Structures of ortho-quinone and para-quinone methide skeletons. 
 
Catechols such as NDGA can be oxidized to either an ortho-quinone or a para-quinone 
methide129.  The presence of the methoxy groups on SECO’s aromatic rings prevents the 
formation of an ortho-quinone but will allow the formation of a para-quinone methide.  
Figure 1.6 depicts how NDGA and SECO could be oxidized to quinones. 
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Figure 1.6: Oxidation of Nordihydroguaiaretic acid (NDGA) and Secoisolariciresinol 
(SECO) to quinones. 
 
Given their inherent reactivity, quinones cannot be stably isolated from 
biological systems.  Nucleophilic trapping agents, such as glutathione (GSH) are 
required to trap the quinone as a stable adduct130.  Addition of GSH to o-Q molecules 
results in GSH addition on the aromatic ring whereas addition to p-QM results in 
addition at the benzylic position130. 
 
1.3.3.1 Ortho-Quinones and Reactive Oxygen Species 
Ortho-quinones are formed in vivo by oxidative processes such as P450 enzyme 
systems and form by the abstraction of a proton and electron to first form a semi-
quinone radical which can then be further oxidized to the quinone131.  The damage 
caused by o-Q is due to oxidative stress created by the redox cycling process (Figure 
1.7) in which oxygen (O2) can react with the semi-quinone radical to form superoxide 
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(O2-) and the o-Q, which can then be reduced back to the semi-quinone radical by 
reductases84,85.  Superoxide may cause damage on its own or lead to the formation of 
hydrogen peroxide, singlet oxygen and the hydroxyl radical128. 
O
O
R
OH
O
R
H+, e-
O2H+, O2-
Reductases
NAD(P)H
 
Figure 1.7: Redox cycling of ortho-quinones. 
 
ortho-quinones are intermediate in toxicity between meta- and para-
quinones128,132.  Moridani et al determined that in rat hepatocytes, 3-hydroxyanisole was 
more toxic than 2-hydroxyanisole which was more toxic than 4-hydroxyanisole, which 
corresponded to meta-, ortho-, and para-quinones (p-Q), respectively132.  The reason 
that o-Q are more toxic than p-Q is that they are more polarized due to a lack of 
symmetry in their structure128.  The increased polarization makes the carbon atom of the 
carbonyl group more electron deficient and thus more likely to seek out cellular 
nucleophiles128.   Quinone methides (QM) however are even more polarized than o-Q 
and p-Q which makes them much more chemically reactive.  Isomerization of o-Q to p-
QM can add complexity to the damage which can be caused by quinones. 
 
1.3.3.2 Para-Quinone Methides and Adduct Formation 
A requirement for the ability of o-Q to isomerize to p-QM is that there must be at 
least one benzylic proton available for abstraction131 (Figure 1.8).  Bolton et al 
determined that 4-allyl-o-quinones can spontaneously rearrange to p-QM129.  The 
conclusions were drawn based on microsomal experiments where o-Q was formed only 
in the presence of GSH during the oxidation of safrole.  If GSH was added 10 minutes 
after the initial incubation period, then a mixture of o-Q and p-QM was formed.  The 
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rate of isomerization of o-Q to p-QM is enhanced when there is extended π-conjugation 
at the para or 4-position of the catechol molecule130 and when the acidity of the benzylic 
proton is increased133. 
O
O
R
O
OH
R
ortho-quinone para-quinone methide 
Figure 1.8: Isomerization of ortho-quinone to para-quinone methide. 
 
Quinone methides differ from o-Q in that one of the carbonyl oxygen molecules 
is replaced by a methylene group131, thus catechols like NDGA can be converted to 
either an o-Q or a p-QM however phenols like SECO can only be converted to p-QM 
(see Figure 1.6).   The p-QM are more electrophilic at the benzylic carbon and more 
reactive than the o-Q which makes them more likely to undergo adduction to cellular 
nucleophilic macromolecules such as DNA and proteins134-136.  Quinone methides, like 
o-Q may also be formed via P450 oxidation137.  Figure 1.9 depicts the position at which 
nucleophiles would form adducts with the electrophilic p-QM. 
O
O(CH3)
R
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OH
O(CH3)
R Nucleophile  
Figure 1.9: Nucleophilic addition to para-quinone methides. 
 
1.4 Xenobiotic Metabolism and Cytochrome P450 Enzymes 
The cytochrome P450 enzymes are a family of Phase I enzymes responsible for 
the metabolism of the majority of xenobiotics, including drugs, toxicants, natural 
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products and environmental contaminants, encountered by the body.  Cytochrome P450 
enzymes are heme centred and known as monooxygenase or mixed-function oxidase 
enzymes.  Although the majority of P450 reactions take place within the liver, P450 
enzymes are also located throughout the body in the small intestine, kidney, skin, lungs 
and brain.    
In humans, CYP1A2, CYP2C9/19 and CYP3A4/5 comprise 13%, 19% and 34% 
or the isoforms present in liver, respectively138.  The majority of clinically relevant drugs 
are metabolized by CYP2C and CYP3A and CYP2C9/19, and CYP2D6 account for the 
most frequent metabolically-relevant polymorphisms138.  The majority of the 
bioactivation reactions observed are due to metabolic activation by CYP1A138.    
Phase I P450 enzymes function to increase the water solubility of xenobiotics by 
hydroxylation, dealkylation, and double bond oxidation, in order to enhance excretion 
however in the process sometimes compounds can become bioactivated138.  
Bioactivation results in the production of an electron deficient molecule which can react 
with electron rich cellular macromolecules, such as proteins, and result in enzyme 
inhibition and/or organ toxicity139-141.  
 
1.4.1 Cytochrome P450 Inhibition 
Interactions of xenobiotics with P450 can be a mechanism of toxicity and may 
result in inhibition of P450 enzymes by either reversible or irreversible 
mechanisms142,143. 
Irreversible, mechanism-based inhibition occurs when a xenobiotic goes through 
the catalytic cycle of the P450 and is bioactivated to a reactive intermediate which 
covalently binds with the heme or apoprotein portion of the enzyme resulting in 
cessation of further P450 activity144,145.  Irreversible inhibitors are identified in 
microsomal incubations by a decrease in substrate formation in a time and 
concentration-dependant manner.  Mechanism-based inhibition can also result in 
covalent binding of the newly bioactivated, electron deficient molecule to electron rich 
proteins or nucleic acids which can lead to either inactivation or hapten formation which 
can illicit an immune response144,146.  If the bioactivated compound binds to P450 the 
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only way to restore function is de novo synthesis of enzyme.  Reversible inhibition on 
the other hand does not result in destruction or loss of P450 function. 
 
1.4.1.1 Mechanisms of Reversible Enzyme Inhibition  
Reversible inhibition is generally categorized into three types: Competitive, Non-
competitive, and Uncompetitive147.  Competitive inhibition is characterized by an 
inhibitor which binds to the same active site145 as the substrate for the enzyme resulting 
in an increase in the KM of the enzyme while the VMax remains consistant148.  
Uncompetitive inhibition occurs when an inhibitor binds to an allosteric site of the 
enzyme-substrate complex which results in a decrease in both KM and VMax of the 
enzyme148.  Non-competitive inhibition is the result of allosteric binding to either the 
enzyme or the enzyme-substrate complex which results in a decrease in VMax of the 
enzyme while KM is unchanged 148.  Mixed type inhibition can also occur and is similar 
to non-competitive binding however it is believed that the inhibitor binds to the enzyme 
and the enzyme-substrate complex with differing affinities147. 
 
1.4.1.2 Inhibition of Cytochrome P450 by Natural Products 
The literature cites many examples of natural compounds that can inhibit P450 
by irreversible mechanisms.  A classic example is the inhibition of intestinal CYP3A by 
bergamottin, a furanocoumarin found in grapefruit juice149.  Bergamottin causes 
irreversible inhibition by binding to the CYP3A4 apoprotein and can also inhibit 
CYP1A2, 2A6, 2C9, 2C19, 2D6 and 2E1 149.  Another non heme-mediated inhibition of 
CYP3A4 is observed with glabridin, an isoflavan isolated from licorice root44.  
Mechanism-based inhibition also occurs by methylenedioxyphenyl-containing lignans 
which are present in the spice Piper cubeba150. 
In the case of capsaicin metabolism by CYP2E1, peroxy radicals are generated 
which react directly with the CYP enzyme in addition to tissue macromolecules151.  
Interestingly the inactivation of P450 seems to be semi-protective in this instance, as 
toxic capsaicin metabolite formation is thus prevented by the loss in enzyme activity. 
Damage may also occur when inhibition is the result of reversible mechanisms 
and bioactivation does not necessarily lead to irreversible inhibition.  The dietary 
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supplement kava is known to cause hepatotoxicity in humans152.  Analysis of an extract 
of kava in human hepatic microsomes identified the formation of several quinoid 
metabolites which were not reactive with the nucleophile GSH152.  Interactions between 
natural products causing P450 inhibition and concurrent pharmaceutical drug treatment 
is also of concern and is becoming increasingly common18,153,154.  Thus it is imperative 
that natural products are investigated for their potential to undergo bioactivation so as to 
minimize toxicities and interactions155. 
 
1.5 Structure Activity Relationships 
Few studies have investigated the relationship between lignan structure and 
activity.  Akiyama et al examined various analogues of MAT and a compound the 
authors called Lio156.  Lio is similar in structure to MAT, except that it contains a furan 
ring in the aliphatic portion of the molecule whereas MAT contains a lactone ring.  It 
appears that the compound that Akiyama et al156 are calling Lio is actually ASECO.  
The authors found that while stereochemistry did seem to play an important role in 
antimicrobial activity of the various lignans, there was no direct relationship which 
could be established156.  The main finding was that a higher oxidation degree at the two 
benzylic positions resulted in higher antimicrobial capacity of the lignans.   The most 
antimicrobial action was seen when there were two carbonyl groups at the benzylic 
position. 
Eugenol and eugenol-related compounds have been studied for associated 
toxicity towards human submandibular gland carcinoma157.  Although eugenol is not a 
lignan, it resembles the structure of one half of a lignan molecule and contains a phenol 
ring with an ortho-methoxy substituent which makes it resemble SECO.  The 
compounds analyzed were all ones which could be converted to QM.  The results of the 
investigations suggest logP and redox potential as having the greatest correlation to 
toxicity for quantitative structure activity relationships157.  Toxicity was associated with 
the production of phenoxy radicals, however the homolytic bond dissociation energy (of 
the phenol oxygen and hydrogen) could not be used to accurately predict the toxicity of 
all of the molecules studied.  The bond dissociation energy could be predicted for mono-
phenols but not dimer-phenols. 
 24
Lastly, Moridani et al looked at a number of catechols, including NDGA, to 
determine quantitative structure activity relationships for toxicity in freshly isolated rat 
hepatocytes158.  The authors found that lipophilicity and pKa were important 
determinants in associating toxicity with structure.  An increased lipophilicity and lower 
degree of ionization and higher pKa (which would essentially dictate the degree of 
ionization in a physiological system) were associated with increased toxicity to 
hepatocytes.  LogP alone was also examined as a possible determinant however it 
appeared to be a less predictable measure of cytotoxicity.   
The few available studies on lignan structure-activity relationships justifies 
further investigations in the area.  The literature clearly shows that toxicity is associated 
with catechols and phenols through convertsion to o-Q and p-QM, respectively.  
However, little evidence exists in the literature for toxicity associated with flaxseed 
phenolic lignans.  Our efforts will be focused on reversible P450 enzyme inhibition and 
bioactivation with possible subsequent P450 inhibition (as a result of bioactivation) as 
potential determinants of lignan toxicity. 
 
1.6 Perspectives 
I knew that the creosote bush lignan NDGA caused toxicity however the 
structurally similar flaxseed lignan SECO had limited toxicity.  I was interested in 
studying this dichotomy of different lignan safety profiles.  In order to gain clearer 
insight into the division between lignan safety and toxicity I studied the oxidative 
metabolism of various lignans to determine whether or not bioactivation may be the key 
factor in the differences in lignan safety profiles.  Investigating the potential of lignans 
to inhibit P450 enzymes as a result of bioactivation or reversible mechanisms was also 
of importance in determining whether lignans in creosote bush or flaxseed would have 
the potential to interact with concurrently used medications.  Given that natural product 
use is on the rise, my studies should provide valuable information about lignan safety.    
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2. PURPOSE OF PROJECT 
 
2.1 Rationale 
There is a growing popularity and availability of herbal products on the market 
today, with an increased need for regulation and rigorous chemical testing performed on 
these products.  To add to the issue, the public has been given the impression that 
because herbals are natural, they must be safe.  An example of adverse effects from 
herbals is illustrated in the hepatotoxicity that is associated with the intake of the lignan 
nordihydroguaiaretic acid (NDGA), a compound found in the creosote bush and in the 
herbal remedy, Chaparral.  The lignan secoisolariciresinol (SECO), found in flaxseed, is 
not hepatotoxic despite being structurally similar to NDGA.  Studying the oxidative 
metabolism of NDGA and SECO will help to provide insight into how lignan structure 
and functional groups may influence natural product safety.  In addition, studying the 
ability of the lignans NDGA, SECO, secoisolariciresinol diglucoside (SDG), 
anhydosecoisolariciresinol (ASECO), enterodiol (ED), enterolactone (EL) and a 
nordihydroguaiaretic acid dibenzocyclooctadiene to inhibit the cytochrome P450 1A2, 
2B, 2C11, and 3A enzymes will provide insight into whether toxicity is mediated 
through bioactivation resulting in mechanism-based or reversible inhibition mechanisms.  
The aims of this project will be accomplished by the following objectives: 
 
2.2 Objectives 
2.2.1 Objective 1 
Study the oxidative metabolism and bioactivation of NDGA and SECO. 
 
2.2.1.1 Specific Aims for Objective 1 
• Develop a high performance liquid chromatography (HPLC) method to separate 
and purify metabolites.
• Perform rat hepatic microsomal incubation experiments using NDGA and GSH, 
and SECO and GSH. 
• Identify products in microsomal incubations using nuclear magnetic resonance 
and mass spectroscopy.   
 
2.2.2 Objective 2 
Study the autoxidation of NDGA. 
 
2.2.2.1 Specific Aims for Objective 2 
• Develop an isocratic HPLC method to allow quantification of an NDGA 
autoxidation product. 
• Perform oxidation studies on NDGA at various pH levels. 
 
2.2.3 Objective 3 
Study the inhibition of CYP isoforms 1A2, 2B, 2C11 and 3A by lignans. 
 
2.2.3.1 Specific Aims for Objective 3 
• Develop an HPLC method to separate and quantify metabolites of testosterone 
metabolism. 
• Develop a fluorescence plate reader method to quantify resorufin methyl ether 
metabolism. 
• Determine the type and extent of CYP inhibition. 
 
2.3 Hypotheses 
1.  NDGA and SECO can be oxidized to quinones in rat microsomal systems. 
2.  Lignans inhibit rat hepatic cytochrome P450 enzymes. 
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3. Oxidative Metabolism of NDGA and SECO 
 
The first objective was to study the oxidative metabolism and bioactivation of 
NDGA and SECO.  Given that NDGA has toxicity reported with its use and SECO is 
comparatively safe I postulated that the toxicity associated with NDGA was linked to 
bioactivation.  The catechol structure of NDGA could give rise to an ortho-quinone (o-
Q) or a para-quinone methide (p-QM) intermediate formed in vivo which could 
potentially be the cause of hepatotoxicity129.  With one hydroxy substituent per phenol 
ring, SECO has the potential to undergo conversion to a para-quinone methide.  
To accomplish the first objective, NDGA and SECO were incubated in rat liver 
microsomes (RLM) in the presence and absence of the nucleophilic trapping agent 
glutathione (GSH).  The metabolites produced were separated by HPLC and the 
structures identified using NMR and mass spectroscopy.   
 
3.1 Materials and Methods 
Preparation of Hepatic Microsomes 
Rats (n=4) were anesthetized with isoflurane and a midline incision made to 
expose the abdominal cavity. A 20g 1 ¼” Terumo Surflo I.V. catheter was inserted into 
the portal vein, the vena cava was nicked to allow outflow, and the livers were perfused 
with room temperature phosphate buffered saline (PBS) for about 3 minutes to clear the 
liver of blood.  Livers were excised, rinsed in PBS, and 6 g pieces were immediately 
flash frozen in liquid nitrogen and stored at -80°C until microsomal preparation.   
Hepatic microsomes were prepared according to the method of Iba et al159. 
Briefly, 0.5 g of liver was homogenized in 2 mL cold homogenization buffer (50 mM 
Tris buffer, 150 mM KCl, 0.1 mM dithiothreitol, 1 mM ethylenediamine tetracetic acid, 
20% glycerol and 0.1 mM phenylmethylsulfonylfluoride) using potter-elvehjem pestle 
and sleeve. The homogenate was transferred to a Beckman (Beckman Coulter Canada, 
Inc. Mississauga, ON) ultracentrifuge tube and spun in a Beckman L8-55 
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Ultracentrifuge at 9000×g for 30 minutes at 4°C.  The supernatant was transferred into 
clean ultracentrifuge tubes and spun at 100 000×g for 30 minutes at 4°C.  The pellet was 
washed with 2 mL 150 mM KCl then similarly spun for an additional 30 minutes at 4°C.  
The pellet was resuspended in 2 mL of 0.25 M sucrose solution and passed through a 
syringe with a 25×g needle.  Microsomes were pooled (n = 4), partitioned into 500 μL 
aliquots in cryogenic microcentrifuge tubes (1.5 mL) and stored at -80°C until use.  
Microsomal protein content was determined by the method of Lowry et al160 
using bovine serum albumin as the standard. Analysis was carried out on an Agilent 
8453E UV-visible spectrophotometer using Chemstation software (Palo Alto, CA, 
USA). Absorbance was measured at 750 nm.  
Hepatic Microsomal Incubation Experiments to Assess Formation of Reactive 
Intermediates 
Microsomal incubation mixtures (1 mL) consisted of cytochrome P450 (1 nmol), 
MgCl2 (5.0 mM), and 50 mM sodium phosphate buffer (pH 7.4). NDGA or SECO 
dissolved in DMSO was added to achieve a final concentration of 0.5 mM (final 
concentration of DMSO was <0.1%) and GSH dissolved in phosphate buffer was added 
to a final concentration of 1.0 mM or 5.0 mM. The mixture was pre-incubated in a 
shaking water bath set to 37°C for 5 min. NADPH (1 mM) was added to initiate the 
reaction. Control incubations included samples with no NADPH, heat-inactivated (95°C 
for 5 min) microsomes or no GSH. Incubations were carried out at 37°C in uncapped 
12×75 mm glass culture tubes in a shaking water bath for 60 min. The reaction was 
terminated by chilling in an ice bath followed by subsequent addition of 50 µL of 
acetonitrile containing internal standard (2mM salicylamide). Samples were centrifuged 
at 20,000×g for 10 min on a Micromax Thermo IEC microcentrifuge. Aliquots of the 
supernatant (150 µL) were analyzed directly by HPLC (NDGA, SECO). 
NMR 
NMR data was obtained on a Bruker AVANCE DPX-500 (Dept of Chemistry, 
University of Saskatchewan) operating at 500 MHz and 125 MHz for proton and carbon, 
respectively and the data analyzed using XWIN-NMR version 3.0.  CD3OD, ME2SO-d6 
and CD3CN were used as solvent.  Residual signals from CD3OD (3.30 ppm (1H) and 
49.0 ppm (13C)), ME2SO-d6 (2.50 ppm (1H) and 39.5 ppm (13C)) and CD3CN (1.94 ppm 
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(1H) and 118.7ppm (13C)) served as internal standards.  Programs for 2-D experiments 
were available from the software package XWINNMR, provided by Bruker.  COSY, 
HMQC and HMBC experiments were performed with gradient pulses.  The 
Distortionless Enhancement by Polarization Transfer (DEPT) experiment together with 
2-dimentional-NMR (2D-NMR) experiments including: Correlation Spectroscopy 
(COSY), Heteronuclear Multiple Quantum Correlation (HMQC), Heteronuclear 
Multiple Bond Correlation (HMBC) and Nuclear Overhauser Effect Spectroscopy 
(NOESY) experiments were performed with gradient pulses. 
 
3.2 Results and Discussion 
Incubation of NDGA in rat liver microsomes resulted in the production of three 
GSH adduct metabolites which were consistent with the formation of o-Q intermediates.  
There was no evidence of p-QM formation in RLM.  HPLC chromatograms for the 
incubations can be found in Chapter 4, Figure 2, page 37 of this thesis and NMR results 
can be found in Chapter 4, NMR Materials and Methods, page 36.  One NGDA-GSH 
and two NDGA-GSH2 metabolites were formed, however both control experiments (no 
NADPH added and heat inactivated microsomes) also generated the same metabolites in 
similar quantities, suggesting that cytochrome P450 enzymes are only partially 
contributing to the metabolism of NDGA.  It appears that autoxidation is the main 
mechanism for NDGA oxidation in RLM161.  Autoxidation of NDGA could be 
visualized over time as the initially clear NDGA solution turned to a reddish-brown 
solution.  Chapter 5 of this thesis details the experiments studying the autoxidation of 
NDGA.   
When SECO was incubated in RLM in both the presence and absence of GSH, 
SECO underwent conversion to lariciresinol without formation of a stable reactive 
quinone intermediate. Lariciresinol was confirmed by comparison with authentic 
standard by HPLC and the result is in agreement with the literature58.  Lariciresinol is 
formed by intramolecular cyclization of the aliphatic hydroxyl group on SECO with the 
distal benzylic carbon. The intramolecular cyclization of SECO to lariciresinol is 
believed to occur sufficiently rapidly, such that it out competes the formation of an 
intermolecular adduction between SECO and GSH.  It is possible that lariciresinol 
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formation is either the result of oxidation to a quinone methide intermediate or the result 
of a radical mediated process although further studies would have to be done to confirm 
this mechanism.   
There was no visual colour change observed over time of SECO in buffered 
solution.  In addition, no lariciresinol formation was observed in the RLM control 
experiments (no NADPH added and heat inactivated microsomes), further suggesting 
that SECO does not autoxidize to any appreciable extent under our conditions.  Thus the 
lack of formation of a reactive intermediate capable of interacting with biological 
nucleophiles via either autoxidation or microsomal oxidation of SECO agrees with the 
lack of toxicity observed with SECO. 
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4. Oxidation of the Lignan Nordihydroguaiaretic Acid 
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1 Abbreviations 
 
16α-OH – 16α-hydroxytestosterone  
ASECO – Anhydrosecoisolariciresinol 
ED – Enterodiol 
EL – Enterolactone 
GSH - Glutathione 
NDGA – Nordihydroguaiaretic acid 
P450 – Cytochrome P450 
SDG – Secoisolariciresinol diglucoside 
SECO – Secoisolariciresinol 
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6.1 Abstract 
Despite their structural similarity, the lignan of creosote bush has demonstrated 
toxicity associated with oral consumption while flaxseed lignans have no reported 
serious toxicity. The ability of lignans to cause either reversible or mechanism based 
inhibition of cytochrome P450 (P450) isoforms in rat hepatic microsomes was studied as 
a potential mechanism for this difference in toxicity potential. Neither creosote bush nor 
flaxseed lignan exhibited P450-mediated bioactivation, although previous reports do 
indicate bioactivation of creosote bush lignan to an ortho-quinone by a non P450-
mediated mechanism. Both creosote bush and flaxseed lignans caused reversible 
inhibition of P450 enzyme activity that involved competitive or mixed-type inhibition. 
However, reversible inhibition was present at nonphysiologically relevant concentrations 
suggesting that the relevance of such interactions in vivo is limited. Interestingly, 
activation of cytochrome P450 isoforms was also observed at low lignan concentrations. 
Our data suggest that P450-mediated bioactivation or reversible inhibition cannot 
explain the differences in toxicity noted between the lignans of creosote bush and 
flaxseed. Whether non P450- mediated bioactivation of creosote bush lignan is 
responsible for the observed toxicity warrants further investigation. 
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6.2 Introduction 
The popularity in natural product use I witness today arose from a growing 
public skepticism about taking “pharmaceutical chemicals” to treat illness. Such 
skepticism was supplanted by a public perception that “medications” from natural 
sources are safer to use and have similar efficacies as their pharmaceutical equivalents. 
The diverse assortment of natural products on the shelves of pharmacies, health food 
stores, and grocery stores attest to this enhanced public demand, but has compelled 
regulatory agencies to question the adequacy of the safety and efficacy data associated 
with the use of these products10. In the current regulatory environment, full realization of 
the wellness and therapeutic value of these natural products can only come about with 
more rigorous assessments of their safety and efficacy.  
This is particularly true of natural products that contain lignans as the principal 
bioactive component. Interest in lignans continues to grow due to an increased 
awareness of their putative health benefits. One such product, Chaparral, contains 
lignans extracted from creosote bush. Creosote bush had centuries of traditional use by 
aboriginal peoples of the Southwestern United States as an effective natural medicine 
and was marketed as an extract of the plant in capsule form based on this historical 
medicinal value106. While traditional creosote bush use appears to be quite safe, chronic 
use of Chaparral led to reports of toxicity33,35,106,107. Nordihydroguaiaretic acid (NDGA) 
is the lignan of creosote bush, which is believed to be responsible for both the 
efficacious and toxic properties of Chaparral27,31,41,162. Wagner and Lewis 1980 
previously reported that NDGA undergoes oxidation to “activated NDGA”121. Billinsky 
et al. 2008 suggest this “activated NDGA” is the result of an autoxidation process to a 
stable dibenzocyclooctadiene  product of NDGA163. Whether this dibenzocyclooctadiene 
is present in traditional creosote bush products or is formed in vivo is not known.  
The recent popularity of lignans from flaxseed, which are currently marketed as 
concentrated extracts of the principal plant lignan, secoisolariciresinol diglucoside 
(SDG), in products such as Brevail™ and Beneflax™, arises from recent promising 
clinical trial evidence of their chemopreventive and therapeutic properties for a variety 
of chronic diseases93,94,164. Following oral consumption, the glucose groups of SDG are 
cleaved to form the aglycone, secoisolariciresinol (SECO), which is further metabolized 
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to the mammalian lignans, enterodiol (ED) and enterolactone (EL), by colonic 
bacteria54,55. Flaxseed also contains smaller amounts of other lignans such as 
mataresinol, and lariciresinol. The presence of anhydrosecoisolariciresinol (ASECO) 
was reported in flaxseed61. However, its actual presence is questioned as the acid 
hydrolysis method used to extract and quantify lignans from flaxseed can convert SECO 
into ASECO 53. Which lignan form mediates the putative health effects is not known, 
but little evidence of toxicity exists with their use, and most clinical trial data identifies 
their relative safety. Interestingly, a comparison of the structure of NDGA from creosote 
bush with the flaxseed lignan, SDG and its aglycone form, SECO, identifies remarkable 
structurally similarity, yet with obvious differences in their safety profiles (Figure 6.1).   
Why lignan in Chaparral is associated with toxicity while lignans from flaxseed 
have limited reported toxicity may relate to differences in their ability to inhibit 
cytochrome P450 (P450) enzymes. Cytochrome P450 enzymes are the principal 
detoxification mechanisms of the body and mediate the elimination of a wide variety of 
drugs, phytochemicals, and environmental toxicants. Consequently, interactions 
involving P450 enzymes are widely reported in the literature. Such P450 enzyme 
interactions often involve P450 inhibition, which may proceed either through 
mechanism-based, irreversible interaction with a P450 enzyme or by a reversible 
competitive interaction between two substrates for the same P450. Both inhibition 
mechanisms represent common underlying mechanisms for toxicity associated with 
pharmaceutical products, phytochemicals and environmental toxicants142. 
Mechanism-based, irreversible inhibition of P450 usually follows from 
bioactivation by P450 to a reactive metabolite that, in turn, covalently binds to the 
enzyme (heme or apoprotein) and prevents further P450 activity144. Enzyme function is 
only restored with synthesis of new enzyme. Alternatively, the reactive metabolite may 
bind to other macromolecules (i.e. protein, nucleic acid) to inhibit their function or form 
a hapten leading to an immune response with toxicological outcomes144.  Hence, P450-
mediated bioactivation to reactive metabolites can represent an important mechanism of 
toxicity associated with natural product use. Reversible competitive interactions at the 
same P450 can also result in toxicity when natural products are present simultaneously 
with other chemicals whose metabolic clearance is predominantly dependent upon a 
 49
particular P450 enzyme142. Competitive interactions, then, may lead to the accumulation 
of a compound and eventual toxicity. Given the potential for significant adverse 
outcomes, evaluation of P450 inhibition is commonly investigated during standard 
safety assessments for drugs, environmental contaminants, and phytochemicals.  
Our purpose was to determine whether mechanism-based, irreversible inhibition 
and/or reversible, competitive P450 inhibition might explain the differences in apparent 
toxicity between oral consumption of naturally occurring lignans from creosote bush, 
which have known toxicity, and flaxseed, which show relative safety. Additionally, such 
information is important to determine whether lignans present a significant concern with 
respect to their potential for P450-mediated interactions. As a proof-of-concept study, rat 
hepatic microsomal systems were employed to investigate the hypothesis that lignan 
from creosote bush undergoes P450-enzyme mediated bioactivation to form reactive 
metabolites while flaxseed lignans do not. Furthermore, I hypothesized that lignan from 
creosote bush inhibits P450 enzyme activity via mechanism-based and/or reversible 
inhibition mechanisms and that glutathione can attenuate the inhibition. The use of rat 
also supports current investigations in our laboratories concerning lignan efficacy and 
pharmacokinetics in rat models of hyperlipidemia and hyperglycemia165. Such 
investigations will make an invaluable contribution to our understanding of the safety of 
natural products containing lignan as the principal bioactive component.  
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Figure 6.1: Structures of lignans derived from Flaxseed1 and Creosote bush2. 
 
6.3 Methods 
Chemicals 
Acetaminophen, NADPH, trifluoroacetic acid, Folin and Ciocalteu’s phenol 
reagent, testosterone, 6β-hydroxytestosterone, 2α-hydroxytestosterone, 
dimethoxyphenylacetone (DMPA), resorufin, resorufin methyl ether (methoxyresorufin), 
glutathione (GSH), nordihydroguaiaretic acid, enterodiol, enterolactone, and 
dimethylsulfoxide were purchased from Sigma-Aldrich Canada Ltd. (Oakville, ON).  
16α-Hydroxytestosterone was purchased from Steraloids Inc. (Newport, RI).  Silca gel 
60 (230-400 mesh) was purchased from EMD Chemicals Inc. (Gibbstown, NJ). 
Secoisolariciresinol diglucoside (>95%) and secoisolariciresinol (>95%) (SECO) and 
were kind gifts from Agriculture and Agri-Food Canada, Saskatoon Research Centre 
(Dr. Alister Muir).  Anhydrosecoisolariciresinol was synthesized from SECO. All other 
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chemicals were of the highest grade required for the experiments and solvents were high 
performance liquid chromatography grade. A MilliQ Synthesis (Millipore, Bedford, 
MA) water purification system provided purified deionized water.  
Animals 
Male Sprague-Dawley (SD) rats, 11 weeks old, were purchased from Charles 
River Laboratories, Inc. (Saint-Constant, PQ).  Rats were housed in a temperature, 
humidity and 12 hour light-dark controlled facility and allowed a one-week 
acclimatization period during which time rats were fed standard laboratory rat chow ad 
libitum and had free access to water. All animal use and care was conducted in 
accordance with the Canadian Council on Animal Care and was approved by the 
University Committee on Animal Care and Supply at the University of Saskatchewan. 
Synthesis of Anhydrosecoisolariciresinol 
Secoisolariciresinol (SECO) (0.254 g, 0.702 mmol) was added to a 100 mL 
round bottom flask and dissolved in 30 mL of methanol. To the flask, 15 drops of 
concentrated HCl was added and the reaction mixture was refluxed at 60ºC for 20 hours 
at which time the reaction was quenched with 30 mL of water and extracted 3 times with 
ethyl acetate (40 mL). The organic layer was washed with 80 mL of sodium bicarbonate 
(0.6 M) and 80 mL of water and then dried with MgSO4. The organic layer was filtered 
and dried to a volume of about 1 mL under vacuum.  A normal phase silica gel flash 
column with 9:1 (dichloromethane:ethyl acetate) was used to purify 
anhydrosecoisolariciresinol (ASECO) to an off-white powder (0.0092 g, 0.268 mmol, 
38% yield). 
Preparation of Hepatic Microsomes 
Rats (n=4) were anesthetized with isoflurane and a midline incision made to 
expose the abdominal cavity. A 20g 1 ¼” Terumo Surflo I.V. catheter was inserted into 
the portal vein, the vena cava was nicked to allow outflow, and the livers were perfused 
with room temperature phosphate buffered saline (PBS) for about 3 minutes to clear the 
liver of blood.  Livers were excised, rinsed in PBS, and 6 g pieces were immediately 
flash frozen in liquid nitrogen and stored at -80°C until microsomal preparation.   
Hepatic microsomes were prepared according to the method of Iba et al159. 
Briefly, 0.5 g of liver was homogenized in 2 mL cold homogenization buffer (50 mM 
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Tris buffer, 150 mM KCl, 0.1 mM dithiothreitol, 1 mM ethylenediamine tetracetic acid, 
20% glycerol and 0.1 mM phenylmethylsulfonylfluoride) using potter-elvheim pestle 
and sleeve. The homogenate was transferred to a Beckman (Beckman Coulter Canada, 
Inc. Mississauga, ON) ultracentrifuge tube and spun in a Beckman L8-55 
Ultracentrifuge at 9000×g for 30 minutes at 4°C.  The supernatant was transferred into 
clean ultracentrifuge tubes and spun at 100 000×g for 30 minutes at 4°C.  The pellet was 
washed with 2 mL 150 mM KCl then similarly spun for an additional 30 minutes at 4°C.  
The pellet was resuspended in 2 mL of 0.25 M sucrose solution and passed through a 
syringe with a 25×g needle.  Microsomes were pooled (n = 4), partitioned into 500 μL 
aliquots in cryogenic microcentrifuge tubes (1.5 mL) and stored at -80°C until use.  
Microsomal protein content was determined by the method of Lowry et al160 
using bovine serum albumin as the standard. Analysis was carried out on an Agilent 
8453E UV-visible spectrophotometer using Chemstation software (Palo Alto, CA, 
USA). Absorbance was measured at 750 nm.  
Hepatic Microsomal Incubation Experiments to Assess Formation of Reactive 
Intermediates 
Microsomal incubation mixtures (1 mL) consisted of microsomal protein (1 
nmol), MgCl2 (5.0 mM), and 50 mM sodium phosphate buffer (pH 7.4). NDGA, SECO, 
or ASECO dissolved in DMSO was added to achieve a final concentration of 0.5 mM 
(final concentration of DMSO was <0.1%) and GSH dissolved in phosphate buffer was 
added to a final concentration of 1.0 mM or 5.0 mM. The mixture was pre-incubated in a 
shaking water bath set to 37°C for 5 min. NADPH (1 mM) was added to initiate the 
reaction. Control incubations included samples with no NADPH, heat-inactivated (95°C 
for 5 min) microsomes or no GSH. Incubations were carried out at 37°C in uncapped 
12×75 mm glass culture tubes in a shaking water bath for 60 min. The reaction was 
terminated by chilling in an ice bath followed by subsequent addition of 50 µL of 
acetonitrile containing internal standard (2mM salicylamide). Samples were centrifuged 
at 20,000×g for 10 min on a Micromax Thermo IEC microcentrifuge. Aliquots of the 
supernatant (150 µL) were analyzed directly by HPLC (NDGA, SECO) or UPLC-MS 
(for ASECO where the analysis was conducted as a kind gift from Dr. Muir, Agriculture 
and Agri-Food Canada). 
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 Hepatic Microsomal Incubation Experiments to Assess Cytochrome P450 Enzyme 
Inhibition 
Inhibition of cytochrome P450 1A2, 2B, 2C11, and 3A2 by lignans was 
determined with assessment of P450 specific probe substrate metabolite pathways. The 
activities of CYP3A, 2B/2C11, 2C11 and 1A2 were monitored by measuring the 
formation of 6β-hydroxytestosterone, 16α-hydroxytestosterone, 2α-hydroxytestosterone, 
and resorufin formation, respectively. The lignans were first tested to identify possible 
mechanism-based inhibition of P450 enzymes. The microsomal protein concentration 
(0.5 mg/mL) and incubation time (15 min) were based upon conditions reported by 
Vuppugalla and Mehva 166 for the testosterone metabolites and 0.4 mg/mL with 
incubation time of 8 min according to Elbarbary et al.167 for the resorufin assays, 
conditions that gave linear metabolite formation velocities. 
Lignans at various concentrations were added to microsomal incubation mixtures 
(500 µL final volume for testosterone; 140 µL final volume for methoxyresorufin) 
containing microsomal protein (0.5 mg/mL for testosterone, 0.4 mg/mL for 
methoxyresorufin), MgCl2 (5.0 mM for testosterone; 2.0 mM for methoxyresorufin), and 
potassium phosphate buffer (pH 7.4; 80 mM for testosterone; 50 mM for 
methoxyresorufin) and pre-incubated in a shaking water bath set to 37ºC for 5 min. 
Lignans were dissolved in DMSO (final concentration of DMSO was <0.1%), except for 
SDG and SECO, which were dissolved in phosphate buffer. NADPH (1 mM) was added 
to initiate the reactions, which were allowed to incubate for 0, 5, 10 or 20 minutes before 
the addition of specific P450 probe substrate. The final concentrations of testosterone 
and resorufin were 250 µM (but 50 uM for ED, EL and Dibenzocyclooctadiene ) and 0.5 
µM, respectively. The samples were incubated at 37ºC for 15 minutes following 
testosterone addition and 8 min following methoxyresorufin addition. The reaction was 
terminated by chilling in an ice bath and subsequent addition of 50 µL (testosterone) or 
60 µL (methoxyresorufin) of ice cold acetonitrile containing internal standard (1 mM 
dimethylphenylacetone as the internal standard for SDG, or 100 μM acetaminophen as 
the internal standard for all other lignans for the testosterone assay).  No internal 
standard was used for the methoxyresorufin assay. Samples were centrifuged at 
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20,000×g for 10 min (Micromax Thermo IEC). Aliquots of the supernatant (150 µL) 
were analyzed directly by HPLC. Control incubations contained either no NADPH or 
heat-inactivated (95°C for 5 min) microsomes. All reactions were performed in 
triplicate. 
For assessment of lignan inhibition of P450 enzyme activity by reversible 
inhibition mechanisms, lignans at various concentrations were added to microsomal 
incubation mixtures as above. The probe substrates, testosterone and methoxyresorufin, 
were also added at various concentrations representing the approximate values of ½ KM, 
KM, 2KM and the VMax concentrations. The mixture was pre-incubated in a shaking water 
bath set to 37ºC for 5 min.  NADPH (1 mM) was added to initiate the reactions, which 
were allowed to incubate for 15 minutes. The reaction was terminated and processed as 
above. Control incubations contained either no NADPH or heat-inactivated (95°C for 5 
min) microsomes.  
High Performance Liquid Chromatography Assays and Analysis of Resorufin 
For NDGA and SECO microsomal incubations, 150 µL of microsomal 
suspension supernatants were injected onto a 250 × 4.6 mm Alltech ODS-2, 5 µm, C-18 
column at a flow rate of 1.5 mL/min with detection wavelength monitored at 280 nm.  
The mobile phase consisted of A: Acetonitrile with 0.1% TFA and B: 0.1% TFA in 
water. For NDGA a gradient of 5% A for 3 min, increased to 20% A over 4 min, 
isocratic for 3 min, increased to 35% A over 26 min, increased to 90% A over 5 min and 
then held isocratic for 4 min was used. For SECO a gradient of 10% A for 5 min, 
increased to 40% A over 25 min, increased to 60% A over 10 min was used. 
The analysis of the ASECO microsomal incubations was a kind gift from 
Agriculture and Agrifood Canada, Saskatoon, SK.  A Synapt HDMS System Waters 
Acquity UPLC System with Waters Acquity PDA and Synapt Q-TOF in negative 
electrospray mode with Masslynx 4.1 software were used. Ten µL of microsomal 
suspension supernatants were injected onto a 50 × 2.1 mm, 1.7 µm, C-18 Waters BEH 
column at a flow rate of 0.6 mL/min with scanning UV detection from 200 – 400 nm. 
The mobile phase consisted of A: Acetonitrile and B: 1% FA in water. A gradient 
starting with 5% A, increased to 95% A over 2.6 min, and then decreased to 5% A over 
2.08 min and held isocratic for 0.32 min was used. 
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The activities of CYP3A, 2B/2C11 and 2C11 were monitored by measuring the 
formation of 6β-, 16α- and 2α-hydroxytestosterone, respectively, by an HPLC assay of 
Pfeiffer and Metzler168 with modifications. Briefly, 150 μL aliquots of microsomal 
incubation supernatants were injected onto a 250 × 4.6 mm Alltech ODS-2, 5 µm, C-18 
analytical column with a 7.5 mm × 4.6 mm Allsphere ODS-2 C18 5μm guard column at a 
flow rate of 1.0 mL/min with detection wavelength set at 240 nm.  The mobile phase 
consisted of A: Acetonitrile with 0.1% trifluoroacetic acid (TFA) and B: 0.01% TFA in 
water.  A gradient of 20% A increased to 25% A over 10 min, held isocratic for 5 min 
increased to 70% A over 10 min was used. Linear calibration curves were constructed 
from known concentrations of each testosterone metabolite (ranging from 0.4 to 25 μM) 
added to microsomal incubation suspensions (total volume 0.5 mL) containing heat-
inactivated microsomes (95°C for 5 min) and 50 µL of the internal standard solution (1 
mM dimethylphenylacetone as the internal standard for SDG, or 100 μM acetaminophen 
as the internal standard for all other lignans). Coefficients of determination were all 
greater than 0.999 and the relevant slope and y-intercept values were statistically 
different from zero (p < 0.005). Three quality control (QC) samples at 0.4, 1, and 10 μM 
were prepared independent of those used for the calibration curves and used as 
acceptance criteria for individual analysis runs. The calibration samples were processed 
as above and the supernatant was injected directly onto the analytical column for 
immediate HPLC analysis. Metabolite concentrations were calculated by interpolation 
from the linear calibration curve using measured metabolite to internal standard peak 
height ratios. Intra- and interday precision was <15% for each metabolite, respectively, 
and accuracy was within 15% of the nominal value for all testosterone metabolites. 
Quality control samples at three different concentrations in duplicate were randomly 
interspersed during the HPLC analysis and served as the acceptance criteria for a 
particular analysis. 
The activity of CYP1A2 was monitored by measuring the formation of resorufin 
from methoxyresorufin using a 96-well fluorescence plate-reader method. A Biotek 
(Winooski, VT) Synergy HT plate reader with a built in plate shaker and chamber heater 
(37°C) was used to analyze the samples. Fluorescence detection employed an excitation 
wavelength of 530 nm and emission wavelength of 590 nm and Gen5 (version 1.00.14) 
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software was used to analyze the data. Linear calibration curves were constructed from 
known concentrations of resorufin (ranging from 5 to 200 nM) added to microsomal 
incubation suspensions (total volume 0.5 mL) containing heat-inactivated microsomes 
(95°C for 5 min) and metabolite concentrations in unknown samples (from which had 
the blank fluorescence values had been subtracted) interpolated from the standard curve. 
Coefficients of determination were all greater than 0.999 and the relevant slope and y-
intercept values were statistically different from zero (p < 0.005). The intraday and 
interday accuracy fell within the allowable 15% variation. Quality control samples at 5, 
30, and 150 nM in duplicate were randomly interspersed during the HPLC analysis and 
served as the acceptance criteria for a particular analysis. 
Data and Statistical Analysis  
For time and concentration dependant inhibition studies, the % inhibition of 
activity for each lignan concentration was plotted versus pre-incubation time using 
Microsoft Excel (Seattle, WA). The formation of metabolite was plotted against log 
inhibitor concentrations to estimate an apparent IC50 value when possible using a 
nonlinear regression analysis with GraphPad Prism 4.0. Otherwise, data was reported as 
a %inhibition from control (ratio of the rate of metabolism in the presence of lignan 
inhibitor relative to rate in the absence of lignan inhibitor). For reversible inhibition 
studies, the inverse of enzyme velocity versus inverse probe substrate concentration was 
plotted to generate Lineweaver-Burke plots using Microsoft Excel. All data is reported 
as mean ± CV (coefficient of variation). 
 
6.4 Results 
Cytochrome P450-Mediated Formation of Reactive Metabolites 
Since SDG is unlikely absorbed due to the polar nature of the glycosidic groups, 
NDGA and SECO were investigated for their potential to undergo hepatic P450-
mediated bioactivation to a reactive intermediate. ASECO was also examined as its 
structure is intermediate of NDGA and SECO. With respect to NDGA, Billinsky et al., 
2007 had previously reported that NDGA underwent autoxidation and conversion via an 
ortho-quinone reactive intermediate to three glutathione (GSH) adducts161. Furthermore, 
in the absence of GSH NDGA autoxidation resulted in the formation of a novel 
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dibenzocyclooctadiene163. SECO was metabolized to lariciresinol both in the presence 
and absence of GSH and no GSH adducts were observed following microsomal 
incubations (data not shown). 
For ASECO, all control experiments showed no product formation; however, in 
the presence of GSH a product peak in MS-ESI(-) with a m/z 648.19 [M-H]- was 
observed (data not shown). This mass is consistent with the formation of an ASECO-
GSH adduct, which is likely derived from an ASECO para-quinone methide. 
 
Mechanism-Based Inhibition of Cytochrome P450 Enzymes 
To determine whether lignans result in mechanism-based inhibition of P450 
enzymes initial experiments examined the extent of inhibition as a function of pre-
incubation time and lignan concentration.  
SDG did not cause mechanism-based inhibition of any P450 isoform at any 
concentration tested (Figure A1). The data also suggests that SDG does not cause 
reversible inhibition of P450 isoforms, as metabolite formation remained the same at 
pre-incubation time 0 at all SDG concentrations tested (Appendix A, Figure A1).  
SECO did not cause significant inhibition of CYP1A2 (Figure A2a). SECO 
inhibited CYP3A in a concentration-dependent but not time-dependent manner 
suggesting that SECO is a reversible inhibitor of the three isoforms. Reversible 
inhibition is consistent with the lack of GSH adduct formation following microsomal 
incubation of SECO in the presence of GSH. However, at 2000 μM SECO inhibited 6β-, 
16α- and 2α-hydroxytestosterone formation by only 36.2 ± 7.26%, 65.7 ± 8.36% and 
64.4 ± 6.36%, respectively. Such concentrations are substantially greater than the levels 
anticipated under physiological conditions (25-100 μM)169.  
ASECO caused limited inhibition of CYP1A2, 2B, and 2C11 (Figure A3), with 
moderate inhibition of CYP3A at the highest concentration (100 µM) caused 49.2 ± 
1.8% inhibition after 20 minutes preincubation. As with SDG and SECO, ASECO 
showed concentration-dependent but not time-dependant inhibition which suggests P450 
inhibition by reversible mechanisms.   
Enterodiol (ED) failed to inhibit P450 activity and rather caused activation of 
CYP1A2, 3A, 2B and 2C11 activity particularly at lower concentrations (Figure 6.2). 
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Although an apparent inhibition of CYP3A activity was observed after a 20 min pre-
incubation (Figure 6.2b), control samples without ED showed a large %CV of 91.8% 
relative to the samples pre-incubated with ED for 20 min.   
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Figure 6.2: Cytochrome P450 enzyme activity (as percent of control) as a function of 
Enterodiol (ED) concentration and pre-incubation time. a) CYP1A2, b) CYP3A, c) 
CYP2B/2C11 and d) CYP2C11. Enterodiol (closed diamond = 0 µM; closed square = 50 
µM; closed triangle = 100 µM; symbol ‘x’ =  250 µM; open circle = 500 µM) was pre-
incubated in pooled male rat hepatic microsomes (n=4) for different time periods. At the 
end of each pre-incubation period, testosterone (50 µM) and methoxyresorufin (0.5 µM) 
was added and metabolite formation was determined after a 15 min and 8 min reaction 
time, respectively.  Each point is the mean of 3 replicates ± percent coefficient of 
variation. 
 
EL caused concentration-dependent, but not time-dependent, inhibition of 
CYP1A2 and only at high concentrations with 500 µM EL inhibiting CYP1A2 to 14.3 ± 
23% that of control (Figure A4). EL also caused concentration-dependent inhibition of 
CYP3A. Interestingly, EL caused activation of 16α-hydroxytestosterone (16α-OH) 
formation, a metabolite pathway shared by CYP2B and CYP2C11. Given the ability of 
EL to inhibit 2α-OH formation, a pathway largely catalyzed by CYP2C11, increased 
16α-OH formation may be due to activation of CYP2B activity by EL.  
NDGA generally caused concentration-dependent but not time-dependent 
inhibition of all CYP isoforms (Figure A5). We anticipated that NDGA could be an 
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irreversible inhibitor given its ability to form a reactive ortho-quinone intermediate. 
Since this is an autoxidation process and not P450 catalyzed process, it appears that the 
ortho-quinone does not inhibit P450 in vitro161,163. Generally, marked inhibition was not 
observed until NDGA concentrations reached 100 μM or higher. At a pre-incubation 
time of 20 minutes and a concentration of 200 µM, NDGA inhibited CYP1A2, 2B/2C11 
and 2C11 to 3.55 ± 12.0%, 21.2 ± 8.81% and 21.2 ± 9.37% of control, respectively. 
NDGA caused complete inhibition of formation of 6β-OH via CYP3A at pre-incubation 
time of 20 minutes and a concentration of 200 µM.  
The NDGA dibenzocyclooctadiene did not cause significant inhibition of 
CYP2B/2C11 and did not cause time-dependant inhibition of any of the tested isoforms 
(Figure A5). The NDGA dibenzocyclooctadiene significantly inhibited CYP3A and 
CYP1A2 to 42.9 ± 3.6%, and 13.9 ± 4.3% of control, respectively, at 100 µM. 
 
Reversible Inhibition of Cytochrome P450 Enzymes 
To determine whether lignans inhibit specific P450 enzymes through reversible 
mechanisms, we monitored the metabolite formation of P450-probe substrates by rat 
hepatic microsomes in the presence of different concentrations of lignan and probe 
substrates. Since time- and concentration-dependent experiments indicated that SDG and 
ED were neither reversible nor irreversible inhibitors of P450 enzyme activity, we 
excluded SDG and ED from our evaluations for reversible inhibition. We estimated the 
% inhibition at each lignan concentration and when possible estimated the IC50 values to 
provide a measure of potency of the inhibition. Lineweaver-Burke plots were 
constructed to determine the mechanism of inhibition. HPLC results from lignan 
incubations indicated substrate depletion at a testosterone concentration of 25 µM, 
representing ½ Km for the substrate. Consequently, this concentration was not included 
in any of the graphical representations and analysis. 
SECO caused a concentration-dependent decrease in 6β-OH formation, which is 
mediated by CYP3A (Figure 6.3a). A plot of 6β-OH formation (at KM) as a function of 
the logarithmic concentration of SECO yielded an IC50 value of 373 µM (95% CI 266-
523). A Lineweaver-Burke plot showed a pattern almost consistent with that of 
competitive inhibition, but the lines intersected in the upper right hand quadrant near the 
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y-axis (not shown). This suggests SECO inhibits CYP3A activity consistent with 
atypical Michaelis-Menten kinetics170,171.  
The formation of 16α-OH testosterone, representing CYP2B/2C11 activity, was 
largely unaffected by SECO at testosterone concentrations of 100 and 250 µM (Figure 
6.3b). At 50 µM testosterone, SECO concentrations ≥50 µM increased the formation of 
16α-OH testosterone. Since CYP2C11 activity was generally unaffected by SECO 
(Figure 6.3c), SECO-mediated activation of CYP2B likely explains the increased 
formation of 16α-OH testosterone. The percent of control activity of the various CYP 
isoforms tested at KM, 2×KM and VMax testosterone is summarized in Table 6.1.  
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Figure 6.3: Secoisolariciresinol (SECO) concentration dependent inhibition of a) 
CYP3A, b) CYP2B/2C11 and c) CYP2C11 using testosterone  (solid bar = 50 µM; open 
bar = 100 µM; stipled bar = 250 µM) as the probe substrate in incubation reactions (15 
min) with pooled (n=4) male, rat liver microsomes. Each point represents the mean of 3 
replicates ± percent coefficient of variation. 
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Table 6.1: The percent of control activity (mean ± % CV) for the formation of 6β-, 16α- and 2α-hydroxytestosterone (OHT) in pooled 
(n=4) rat liver microsomes by 50 and 1600 μM Secosiolariciresinol (SECO) at the KM, 2×KM and ~VMax of testosterone. 
 6β-OHT (CYP3A) 16α-OHT (CYP2B/2C11) 2α-OHT (CYP2C11) 
 Percent of Control Activity  
(mean ± % CV) 
Percent of Control Activity  
(mean ± % CV) 
Percent of Control Activity  
(mean ± % CV) 
Testosterone/ 
Methoxyresorufin  
SECO  
50 μM 
SECO  
1600 μM 
SECO  
50 μM 
SECO  
1600 μM 
SECO  
50 μM 
SECO  
1600 μM 
KM 90.7 ± 5.0 29.0 ± 11 117.5 ± 5.1 172 ± 8.1 106.1 ± 1.7 86.0 ± 7.6 
2KM 86.4 ± 1.1 31.8 ± 11 91.0 ± 0.5 87.4 ± 5.2 97.3 ± 0.5 75.0 ± 4.0 
VMax 91.9 ± 3.6 42.4 ± 3.1 98.4 ± 2.8 80.9 ± 5.2 97.1 ± 2.3 71.9 ± 3.3 
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Figure 6.4: Anhydrosecoisolariciresinol (ASECO) concentration dependent inhibition of 
a) CYP1A2 and b) CYP3A using methoxyresorufin (solid bar = 0.5 µM; open bar = 1 
µM; stipled bar = 2.5 µM) and testosterone (solid bar = 50 µM; open bar = 100 µM; 
stipled bar = 250 µM) as the probe substrates, respectively, in incubation reactions (15 
min and 8 min, respectively) with pooled (n=4) male, rat liver microsomes. Each point 
represents the mean of 3 replicates ± percent coefficient of variation.  
Pre-incubation time- and concentration- dependant experiments showed that 
ASECO was not an inhibitor of CYP2B/2C11. Due to overlapping and unresolvable 
HPLC peaks, the inhibition of CYP2C11, measured by 2α-OH testosterone formation 
could not be assessed.  
ASECO maximally inhibited CYP1A2 when methoxyresorufin concentration 
was at the KM of the enzyme, with the greatest extent of inhibition occurring at 100 µM 
ASECO (70.8 ± 3.9% of control) (Figure 6.4a). Further increases in the extent of 
inhibition at higher ASECO concentrations was not observed, but this may be due to an 
inability to completely solubilize ASECO. ASECO generally caused a concentration-
dependent inhibition of CYP3A at all testosterone concentrations, although the pattern 
of inhibition became inconsistent at ASECO concentrations beyond 100 µM, which may 
due to solubility issues (Figure 6.4b). The percent of control activity of the formation of 
resorufin and 6β-OH tested at KM, 2×KM and VMax of methoxyresorufin and testosterone 
is summarized in Table 5.2. A plot of the 6β-OH formation (at KM) as a function of the 
logarithmic concentration of ASECO yielded an IC50 value of 36.4 µM (95% CI 21.9-
60.3). The IC50 value for CYP1A2 inhibition was greater than 200 µM. A Lineweaver-
Burke plot gave parallel lines, a pattern consistent with uncompetitive inhibition (not 
shown). 
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 Table 6.2: The percent of control activity (mean ± % CV) for the formation of 6β-
hydroxytestosterone (OHT) and resorufin in pooled (n=4) rat liver microsomes by 25 
and 100 μM Anhydrosecosiolariciresinol (ASECO) at the KM, 2×KM and ~VMax of 
testosterone or methoxyresorufin. 
 Resorufin (CYP1A2) 6β-OHT (CYP3A) 
 Percent of Control Activity  
(mean ± % CV) 
Percent of Control Activity  
(mean ± % CV) 
Testosterone/ 
Methoxyresorufin  
ASECO  
25 μM 
ASECO  
100 μM 
ASECO 
25 μM 
ASECO 
100 μM 
KM 89.6 ± 19.5 70.8 ± 3.9 74.0 ±3.5 40.9 ± 6.5 
2KM 87.5 ± 14.1 86.4 ± 14.0 55.5 ± 7.8 15.6 ± 10.2 
VMax 102.6 ± 3.8 94.7 ± 12.5 59.7 ± 12.2 65.2 ± 28.7 
 
Enterolactone caused CYP2B/2C11 activation in time- and concentration-
dependent experiments and thus was not examined for reversible inhibition of these 
enzymes. EL maximally inhibited CYP1A2 when methoxyresorufin concentration was 
at the KM of the enzyme (Figure 6.5a). EL also caused a concentration-dependent 
decrease in resorufin formation at 2×KM and VMax methoxyresorufin concentrations 
(Figure 6.5a). At the Km of testosterone, EL did not inhibit CYP3A activity and at 500 
µM EL, a 3-fold increase in metabolite formation was observed (Figure 6.5b). However, 
at 2×KM and VMax testosterone concentrations, EL generally caused a concentration-
dependent decrease in CYP3A-mediated 6β-OH formation (Figure 6.5b).  For 
CYP2C11, at the KM of testosterone, EL generally increased the rate of 2α-OH 
formation at all EL concentrations. However, EL caused pronounced inhibition at 2×KM 
and VMax testosterone concentrations for the enzyme (Figure 6.5c). Plots of metabolite 
formation (at KM) as a function of the logarithmic concentration of EL yielded an IC50 
values of 441 µM (95% CI 115-1695), 72.9 µM (95% CI 54.0-98.2) (determined at the 
VMax due to activation at KM) and 104 µM (95% CI 85.7-127) (determined at the VMax 
due to activation at KM) for CYP1A2, CYP3A and CYP2C11, respectively. The percent 
of control activity of the various CYP isoforms tested at KM, 2×KM and VMax of 
methoxyresorufin or testosterone is summarized in Table 6.3.  
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Figure 6.5: Enterolactone (EL) concentration dependent inhibition of a) CYP1A2, b) 
CYP3A and CYP2C11 using methoxyresorufin (solid bar = 0.5 µM; open bar = 1 µM; 
stipled bar = 2.5 µM) and testosterone (solid bar = 50 µM; open bar = 100 µM; stipled 
bar = 250 µM) as the probe substrates, respectively, in incubation reactions (15 min and 
8 min, respectively) with pooled (n=4) male, rat liver microsomes. Each point represents 
the mean of 3 replicates ± percent coefficient of variation. 
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Table 6.3: The percent of control activity (mean ± % CV) for the formation of resorufin, and 6β-, 16α- and 2α-hydroxytestosterone 
(OHT) in pooled (n=4) rat liver microsomes by 100 and 500 μM Enterolactone (EL) at the KM, 2×KM and ~VMax of methoxyresorufin 
or testosterone. 
 
 Resorufin (CYP1A2)  6β-OHT (CYP3A) 16α-OHT (CYP2B/2C11) 2α-OHT (CYP2C11) 
 Percent of Control Activity  
(mean ± % CV) 
Percent of Control Activity 
(mean ± % CV) 
Percent of Control Activity 
(mean ± % CV) 
Percent of Control Activity 
(mean ± % CV) 
Testosterone/ 
Methoxyresorufin  
EL 
100 μM 
EL 
500 μM 
EL 
100 μM 
EL 
500 μM 
EL 
100 μM 
EL 
500 μM 
EL 
100 μM 
EL 
500 μM 
KM 74.2 ± 13.8 24.7 ± 23.7 95.1 ± 26.8 309.9 ± 26.0 262.7 ± 17.1 302.5 ± 11.4 176.2 ± 13.2 120.2 ± 48.1 
2KM 97.4 ± 12.2 42.6 ±1.0 45.5 ± 4.2 55.0 ± 0.7 86.9 ± 1.8 61.9 ± 2.1 51.0 ± 2.9 42.4 ± 1.9 
VMax 96.7 ± 1.1 64.7 ± 1.6 52.0 ± 6.4 50.2 ± 2.3 75.4 ± 5.4 60.1 ± 2.7 53.9 ± 5.5 43.0 ± 1.7 
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Lineweaver-Burke plots were difficult to interpret for EL inhibition of CYP1A2, 
although the pattern was somewhat consistent with that of competitive inhibition, with 
the lines intersecting in the upper right hand quadrant (not shown). However, the pattern 
of the plots for CYP2C11 and CYP3A were consistent with noncompetitive inhibition 
by EL.  
In general, NDGA caused a concentration-dependent decrease in CYP1A2, 
CYP3A, CYP2B and CYP2C11 activity (Figure 6.6).  For CYP1A2, NDGA caused 
more prominent inhibition at the KM of methoxyresorufin (Figure 6.6a), but for the 
CYP3A, CYP2B/2C11, and CYP2C11, NDGA caused most pronounced inhibition of 
testosterone metabolite formation at the VMax for testosterone (Figure 6.6a, 6.6b, 6.6c). 
Furthermore, at the KM of testosterone, NDGA increased the 16α- and 2α-hydroxylation 
of testosterone, index pathways for CYP2B/2C11 and CYP2C11, respectively. 
Activation of metabolism was more pronounced for 16α-OH formation. The IC50 values 
were calculated at the KM of the substrate for CYP1A2 and CYP3A and at VMax for 
testosterone for CYP2B/2C11 and CYP2C11, as activation was observed at the KM for 
CYP2B/2C11 and CYP2C11. Plots of metabolite formation as a function of the 
logarithmic concentration of NDGA yielded IC50 values of 63.5 µM  (95% CI 11.8-341), 
97.3 µM (95% CI 49.6-191), 68.7 µM (95% CI 46.4-102) and 96.6 µM (95% CI 55.3-
169) for CYP1A2, CYP3A, CYP2B/2C11 and CYP2C11, respectively. The percent of 
control activity of the various CYP isoforms tested at KM, 2×KM and VMax of 
methoxyresorufin or testosterone is summarized in Table 6.4.  
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Table 6.4: The percent of control activity (mean ± % CV) for the formation of resorufin, and 6β-, 16α- and 2α-hydroxytestosterone 
(OHT) in pooled (n=4) rat liver microsomes by 25 and 200 μM Nordihydroguaiaretic acid (NDGA) at the KM, 2×KM and ~VMax of 
methoxyresorufin or testosterone. 
 
 Resorufin (CYP1A2) 6β-OHT (CYP3A) 16α-OHT (CYP2B/2C11) 2α-OHT (CYP2C11) 
 
Percent of Control Activity 
(mean ± % CV) 
Percent of Control Activity 
(mean ± % CV) 
Percent of Control Activity 
(mean ± % CV) 
Percent of Control Activity 
(mean ± % CV) 
Testosterone/ 
Methoxyresorufin 
NDGA 
25 μM 
NDGA 
200 μM 
NDGA 
25 μM 
NDGA 
200 μM 
NDGA 
25 μM 
NDGA 
200 μM 
NDGA 
25 μM 
NDGA 
200 μM 
KM 84.1 ± 16.2 6.7 ± 13.5 81.8 ± 6.4 17.6 ± 11.7 158.3 ± 6.2 123.2 ± 8.8 118.0 ± 3.9 57.3 ± 8.6 
2KM 100.6 ± 1.7 17.9 ± 4.2 66.6 ± 1.8 12.4 ± 30.7 88.7 ± 4.5 42.2 ± 26.0 93.0 ± 2.9 37.5 ± 26.1 
VMax 109.1 ± 1.1 40.2 ± 7.9 63.6 ± 3.9 11.1 ± 3.5 79.8 ± 3.4 27.6 ± 0.3 88.7 ± 3.8 29.7 ± 0.1 
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Figure 6.6: Nordihydroguaiaretic acid (NDGA) concentration dependent inhibition of a) 
CYP1A2, b) CYP3A c) CYP2B/2C11, and d) CYP2C11 using methoxyresorufin (solid 
bar = 0.5 µM; open bar = 1 µM; stipled bar = 2.5 µM) and testosterone (solid bar = 50 
µM; open bar = 100 µM; stipled bar = 250 µM) as the probe substrates, respectively, in 
incubation reactions (15 min and 8 min, respectively) with pooled (n=4) male, rat liver 
microsomes. Each point represents the mean of 3 replicates ± percent coefficient of 
variation.  
For NDGA dibenzocyclooctadiene, the activity of CYP2C11, as monitored by 
2α-OH testosterone formation, could not be assessed, as the dibenzocyclooctadiene 
eluted at the same retention time as 2α-OH testosterone during the HPLC run. For 
CYP1A2, the dibenzocyclooctadiene caused more prominent inhibition at the KM of 
methoxyresorufin (Figure 6.7a), but for CYP3A and CYP2B/2C11 slightly greater 
inhibition of testosterone metabolite formation at the testosterone VMax was observed 
Lineweaver-Burke plots for NDGA inhibition of CYP1A2 showed a pattern 
consistent with competitive inhibition, but with the lines intersecting in the upper right 
hand quadrant near the y-axis (not shown). For CYP3A the pattern was consistent with 
noncompetitive inhibition. For the CYP2B/2C11 and CYP2C11 pathways, the 
Lineweaver-Burke plots were more difficult to interpret. At higher NDGA 
concentrations, parallel lines suggested uncompetitive inhibition. However, activation of 
these pathways at the KM of testosterone (Figure 6.6c and 6.6d) likely affected the 
overall pattern observed in these plots (not shown). 
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 (Figure 6.7b, 6.7c). At the VMax of testosterone, dibenzocyclooctadiene concentrations of 
50 to 150 µM increased the formation of resorufin, index pathways for CYP1A2 (Figure 
6.7a). Dibenzocyclooctadiene did not cause significant inhibition of CYP2B/2C11 as 
evidenced by no substantial decrease in 16α-OH formation (Figure 6.7c). Plots of 
metabolite formation as a function of the logarithmic concentration of NDGA 
dibenzocyclooctadiene yielded an IC50 value of 36.8 µM (95% CI 25.3-53.6) for 
CYP3A. For CYP1A2, the data did not yield an interpretable due to extensive variation 
in the data. The percent of control activity of the various CYP isoforms tested at KM, 
2×KM and VMax of methoxyresorufin or testosterone is summarized in Table 6.5.  
Lineweaver-Burke plots for dibenzocyclooctadiene inhibition of CYP1A2 
showed a pattern consistent with competitive inhibition, but with the lines intersecting in 
the upper right hand quadrant near the y-axis and for CYP3A the pattern was consistent 
with noncompetitive inhibition (not shown). 
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Figure 6.7: Dibenzocyclooctadiene concentration dependent inhibition of a) CYP1A2, b) 
CYP3A, and c) CYP2B/2C11 using methoxyresorufin (solid bar = 0.5 µM; open bar = 1 
µM; stipled bar = 2.5 µM) and testosterone (solid bar = 50 µM; open bar = 100 µM; 
stipled bar = 250 µM) as the probe substrates, respectively, in incubation reactions (15 
min and 8 min, respectively) with pooled (n=4) male, rat liver microsomes. Each point 
represents the mean of 3 replicates ± percent coefficient of variation.  
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Table 6.5: The percent of control activity (mean ± % CV) for the formation of resorufin, and 6β-, 16α- and 2α-hydroxytestosterone 
(OHT) in pooled (n=4) rat liver microsomes by 12.5, 50, 100 and 200 μM Dibenzocyclooctadiene (DIB) at the KM, 2×KM and ~VMax 
of methoxyresorufin or testosterone 
 Resorufin (CYP1A2) 6β-OHT (CYP3A) 16α-OHT (CYP2B/2C11) 
 
Percent of Control Activity 
(mean ± % CV) 
Percent of Control Activity 
(mean ± % CV) 
Percent of Control Activity 
(mean ± % CV) 
Testosterone/ 
Methoxyresorufin 
DIB  
50 μM 
DIB  
200 μM 
DIB  
12.5 μM 
DIB  
100 μM 
DIB  
12.5 μM 
DIB  
100 μM 
KM 90.3 ± 2.5 45.3 ± 1.0 71.5 ± 7.4 26.9 ± 3.5 96.8 ± 7.0 82.0 ± 2.5 
2KM 107.4 ± 12.4 68.6 ± 12.1 74.0 ± 3.5 21.8 ± 10.0 91.3 ± 4.1 60.4 ± 8.2 
VMax 153.8 ± 12.7 103.4 ± 4.8 70.0 ± 2.2 26.4 ± 8.0 85.4 ± 2.9 59.6 ± 7.0 
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Inhibition of CYP1A2 by Nordihydroguaiaretic Acid in the Presence of Glutathione  
The effect of adding GSH to microsomal incubations before the addition of 
NDGA was studied to determine whether GSH could attenuate inhibition at various time 
and inhibitor concentrations. GSH had little impact on NDGA inhibition of CYP1A2 
activity (Figure A7). The calculated IC50 for NDGA in the presence and absence of GSH 
was 63.5 µM (95% CI 11.8-341) and 80.1 µM (95% CI 22.6-284), respectively, for 
CYP1A2. Interestingly, at 50 µM NDGA, GSH attenuated inhibition, and appeared to 
cause activation of CYP1A2 (Figure A8).  
Summary of Inhibition of Rat CYP3A, CYP2B, CYP2C11 and CYP1A2 by Lignans 
Table 6.6 summarizes the estimated IC50 values for lignan-mediated reversible 
inhibition different P450 isoforms. For lignans that failed to inhibit specific P450 
isoforms the value reported represents the solubility limit for the respective lignan. Table 
6.7 summarizes the type of reversible inhibition mechanism exhibited by each lignan for 
a particular P450 isoform.  
 
Table 6.6: Summary of estimated lignan IC50 values (µM) (with 95% confidence 
intervals displayed in brackets) for CYP1A2, CYP3A, CYP2B/2C11 and CYP2C11. 
IC50 values were determined at probe substrate KM, except where noted.   
 CYP1A2 CYP3A 
CYP2B/ 
CYP2C11 
CYP2C11 
Secoisolariciresinol NDa 
373 
(266-523) 
> 1600 > 1600 
Anhydrosecoisolariciresinol > 200 
36.4  
(21.9-60.3) 
> 200 NDb 
Enterolactone 
441  
(115-1695) 
72.9c  
(54.0-98.2) 
> 500 
 
104c  
(85.7-127) 
Nordihydroguaiaretic 
acid 
63.5 
(11.8-341) 
97.3  
(49.6-191) 
68.7c  
(46.4-102) 
96.6c  
(55.3-169) 
Dibenzocyclooctadiene  NDa 
36.8  
(25.3-53.6) 
NDa NDb 
ND = not determined  
aNo inhibition was observed at any lignan concentration 
bCould not assess due to overlapping peak on high performance liquid chromatography 
cIC50 assessed at VMax 
  
Table 6.7: Summary of the type of P450 enzyme inhibition caused by lignans of creosote 
bush and flaxseed. 
 CYP1A2 CYP3A 
CYP2B/ 
CYP2C11 
CYP2C11 
Secoisolariciresinol NO Competitive NOa NO 
Anhydro-
secoisolariciresinol 
Un-
competitive 
Un-
competitive NO NO 
Enterolactone Competitive Non-competitivea NO
a Non-competitivea 
Nordihydroguaiaretic 
acid 
Competitive Non-competitive 
Un-
competitivea 
Un-
competitivea 
Dibenzocyclooctadiene  Competitive Non-competitive NO 
Could not 
assess 
 
NO = No inhibition was observed 
aActivation of P450 activity was observed. 
 
6.4 Discussion 
In our P450 enzyme inhibition studies with the lignans of creosote bush and 
flaxseed, none of the lignans evaluated caused mechanism-based inhibition of P450 
activity. Most lignans exhibited reversible inhibition of several rat P450 enzymes that 
involved primarily competitive mechanisms, but sometimes showed inhibition more 
characteristic of noncompetitive or uncompetitive mechanisms. However, reversible 
inhibition of P450 activity occurred at concentrations unlikely achieved with usual 
lignan oral consumption levels. At concentrations consistent with therapeutic or 
beneficial effects of lignans, activation of CYP1A2 enzyme activity was observed with 
the creosote bush derived lignans. These data suggest a rather remote potential for 
significant interactions between the lignans and other P450 enzyme substrates through 
either reversible or mechanism-based enzyme inhibition mechanisms.  
Cytochrome P450 enzyme interactions are commonly touted as a mechanism of 
toxicity142,143. In particular, bioactivation, or the metabolic activation of a compound to 
an electrophilic reactive intermediate, which subsequently undergoes covalent binding to 
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 critical cellular macromolecules and interferes with their function, has long-standing 
recognition as a biochemical mechanism of organ toxicity139-141. Several examples exist 
of natural products undergoing P450-mediated bioactivation and irreversible P450 
enzyme inhibition and hepatotoxicity44,149,151,152,172. Furthermore, natural products are 
known to result in significant interactions with coadministered therapeutic agents 
resulting in adverse effects or therapeutic failures18,153,154. With the growing interest in 
lignans for their health and wellness or therapeutic values, assessments of their safety 
are necessary to support their use.  
Structural features of the lignans suggest their potential for oxidation to quinone 
derivatives, a class of compounds known to be electrophilic reactive intermediates129,130. 
Previous studies in our laboratory identified NDGA’s (the major lignan of creosote 
bush) ability to undergo autoxidation to a reactive quinone species161,163, whereas current 
studies indicate that SECO (the aglycone form of the major flaxseed lignan, SDG) 
underwent conversion to lariciresinol without formation of a stable reactive quinone 
intermediate. These studies, in conjunction with the growing interest in their use, 
compelled an investigation into their potential for mechanism-based inhibition and/or 
reversible inhibition of P450 isoforms. The use of in vitro microsomal systems for 
assessments of cytochrome P450 inhibition potential by drug candidates and natural 
products is a commonly employed technique to determine the likelihood for 
pharmacokinetic interactions resulting from P450 enzyme inhibition143.  
We examined the ability of creosote bush and flaxseed lignans to inhibit the 
activity of CYP3A, CYP2C and CYP1A2 enzymes as these isoforms are principally 
involved in the metabolism of drugs and other natural products on the market today. Our 
studies provided no evidence of mechanism-based inhibition of the P450 enzymes by 
either the lignans of creosote bush or flaxseed. The autoxidation of NDGA to a reactive 
intermediate in rat hepatic microsomes161 did not result in the inactivation of P450 
enzyme activity. These findings are not unexpected as the literature suggests ortho-
quinones do not usually undergo adduct formation with cellular macromolecules, instead 
their damage is usually mediated through an increase in oxidative stress128,173,174. 
Although ortho-quinones may isomerize to para-quinone methides in vivo, a quinone 
derivative known to form covalent adducts with cellular macromolecules134, this process 
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 is unlikely to occur as NDGA is substituted at the benzylic carbon, which severely 
hinders the isomerization process130.  
Although our studies provide evidence of reversible inhibition of rat P450 
enzyme activity by the lignans of creosote bush and flaxseed, such inhibition required 
rather high lignan concentrations. The principal creosote bush lignan, NDGA, and its 
autoxidation product, dibenzocyclooctadiene, inhibited CYP3A, CYP2B/2C11 and 
CYP1A2 activity suggesting that these lignans act as general reversible inhibitors of 
P450 activity. Although previous studies showed that in the presence of GSH NDGA is 
oxidized to NDGA-GSH adducts and prevents the formation of NDGA 
dibenzocyclooctadiene163, inhibition of P450 activity was still observed. In the current 
experiments, addition of GSH to microsomal incubations before the addition of NDGA 
did not attenuate the inhibition of CYP1A2 caused by NDGA. These observations 
suggest that that GSH in vivo does not protect against reversible P450 inhibition by the 
creosote bush lignan, NDGA. Interestingly, at lower probe substrate concentrations, 
NDGA caused activation of CYP1A2 activity, while dibenzocyclooctadiene increased 
the metabolite formation of the index pathway for CYP2B/2C11. Although P450 
enzyme activation has been observed for other compounds143,175, the relevance of this 
phenomenon on in vivo metabolism is not known143,176.  
Reversible inhibition of P450 enzyme activity by the flaxseed lignans tended to 
show more specificity than the creosote bush lignans. The principal lignan present in 
flaxseed, SDG, failed to inhibit any P450 enzyme examined. This result was not 
unexpected given the physicochemical characteristics of SDG. Hydrophilic molecules 
tend not to be substrates for P450 enzymes and are primarily eliminated from the body 
via renal elimination mechanisms. Furthermore, studies have failed to detect systemic 
levels of SDG177, suggesting that it is not absorbed from the gastrointestinal tract or 
undergoes extensive first pass metabolism prior to its appearance in the systemic 
circulation. Studies further suggest that this first-pass metabolism occurs at the 
gastrointestinal level, where the glucosidic groups of SDG are cleaved to produce the 
aglycone, SECO57,178. SECO is likely the flaxseed lignan form available for absorption 
following the oral consumption of flaxseed products56,63. 
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 Our data suggest SECO is a more specific inhibitor of P450 enzymes and causes 
a marked reduction in CYP3A activity only at high SECO concentrations. Our data also 
show that SECO activates CYP2B activity at lower probe substrate concentrations. We 
further examined the ability of an additional flaxseed lignan, ASECO, to inhibit P450 
enzyme activity. Whether ASECO is present in flaxseed remains controversial as the 
identification of ASECO in flaxseed may be an artifact of the analytical techniques 
employed by Charlet et al61. Our lab has produced ASECO by acid hydrolysis of SECO 
using the same methods as Charlet et al, 200261. Furthermore, ASECO could be formed 
during the isolation process for lignan enriched flaxseed products such as Beneflax™, 
and with oral consumption of flaxseed lignan products small amounts of ASECO could 
form within the acidic environment of the stomach. Such factors warranted an 
examination of ASECO’s ability to inhibit P450 enzyme activity. ASECO inhibited 
CYP3A and CYP1A2 but had no affect on the index pathways for CYP2B/2C11 in the 
rat. In the presence of GSH, an adduct was formed that was consistent with a para-
quinone methide129,179. Despite this observation, mechanism-based inhibition of P450 
activity was not identified in our studies. 
SDG (and SECO) is often referred to as the precursor for the enterolignans, ED 
and EL56,57,177,178,180. Much of the putative health benefits of flaxseed lignans are 
ascribed to the enterolignan forms, although definitive data for such assertions is 
lacking. Following oral consumption, SDG is converted to SECO, which further 
undergoes metabolism to ED and then to EL by colonic bacterial activity56. The 
literature reports significant systemic and urinary levels of EL and its conjugated 
forms56,80 and much lower levels of ED suggesting that EL and ED are absorbed 
following their conversion within the gastrointestinal tract. This warranted an 
investigation of their potential to inhibit P450 enzyme activity. ED failed to inhibit any 
of the P450 index pathways evaluated in our study. On the other hand, EL inhibited 
CYP3A, CYP1A2, and CYP2C11 suggesting that, like NDGA, EL is a general 
reversible inhibitor of P450 enzymes. Interestingly, EL also activated the CYP2B/2C11 
index pathway, the relevance of which is not known.   
Lineweaver-Burke plots of the inhibition data suggest that lignans largely caused 
reversible inhibition via a combination of competitive, noncompetitive, and 
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 uncompetitive mechanisms. The ability of lignans to activate P450 enzyme activity in 
the presence of low probe substrate concentrations for the P450 index pathways may 
account for the mixed type inhibition we observed143. Nonetheless, our in vitro results 
suggest that potential for pharmacokinetic interactions via inhibition of P450-mediated 
elimination by flaxseed lignans is extremely limited. Concentration at the P450 active 
site is a principal determinant of the potential for clinically relevant interactions181. 
Systemic levels reported in the literature suggest that lignan concentrations achieved at 
the P450 active site would be insufficient to cause significant inhibition. Even following 
oral consumption, when portal vein concentrations and hence, hepatic concentrations, of 
lignans are expected to be much greater than systemic levels, the competing phase II 
reactions (i.e. glucuronidation, sulfation)182,183 would diminish the availability of lignans 
at the P450 enzyme active sites. The clinical use of lignans should not be associated with 
adverse outcomes resulting from inhibition of P450-mediated metabolism. 
In conclusion, our data does not support the hypothesis that the differential 
toxicity between lignans of creosote bush and flaxseed may be due to differences in their 
capacity to undergo P450-mediated bioactivation to electrophilic reactive intermediates 
or reversible P450 enzyme inhibition. NDGA’s autoxidation to a reactive quinone 
intermediate warrants further investigation as a possible mechanism associated with its 
known toxicity. Nonetheless, our in vitro data suggests the potential for inhibition of 
P450-mediated elimination of compounds by the lignans of creosote bush and flaxseed 
is limited. Their use for promotion of health and wellness or for therapeutic reasons 
should not be associated with adverse outcomes resulting from inhibition of P450-
mediated metabolism. For the flaxseed lignans, our in vitro metabolism data is supported 
by the emerging clinical data on flaxseed lignan administration where no adverse effects 
have been reported as of yet. Such promising clinical trial data associated with the 
flaxseed lignans warrants further evaluations of their safety and efficacy, which remains 
a focus in our laboratory.  
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7. GENERAL CONCLUSIONS AND FUTURE DIRECTIONS 
 
7.1 General Conclusions  
The overall aim of this dissertation was to investigate why the lignan NDGA, 
from the creosote bush, is associated with toxicity while the lignans from flaxseed are 
generally considered safe.  Three objectives (Section 2.2) which each had a series of 
specific aims were executed using a variety of laboratory techniques to test the two 
hypotheses (Section 2.3), that NGDA and SECO can be oxidized to quinones in rat 
microsomal systems and also that lignans inhibit rat hepatic cytochrome P450 enzymes.  
The resulting conclusions drawn from the data obtained from the experiments for each 
of the thesis objectives is outlined below. 
 
Objective 1 - Study the oxidation metabolism and bioactivation of Nordihydroguaiaretic 
acid and Secoisolariciresinol. 
To accomplish the first objective, HPLC methods were developed to separate 
and purify oxidized metabolites of NDGA and SECO.  NDGA and SECO were 
incubated in rat liver microsomes (RLM) in the presence and absence of GSH and the 
metabolites produced were identified using NMR and mass spectroscopy.   
Despite being theoretically possible to undergo oxidation to both an ortho-
quinone (o-Q) and a para-quinone methide (p-QM)129,130, we demonstrated that NDGA 
only undergoes conversion to an o-Q in aqueous solution and at physiological pH and 
temperature.  The o-Qs are known to be associated with toxicity and the production of o-
Q reactive intermediates may be responsible for the hepatotoxicity caused by NDGA. 
Three NDGA-GSH adducts, that were consistent with o-Q intermediates, were 
generated in the RLM experiments with GSH and were identified as one NGDA-GSH 
and two NDGA-GSH2.  Both control experiments (No NADPH added and heat 
inactivated microsomes) also generated the same metabolites in similar quantities, 
suggesting that CYP is only partially contributing to the metabolism of NDGA. 
 We did not find any evidence of p-QM formation in RLM.  Although it is 
possible for o-Q to isomerize to p-QM in vivo, this process is unlikely to occur as 
NDGA is substituted at the benzylic carbon, which severely hinders the isomerization 
process130.   
While it was previously determined that NDGA undergoes CYP mediated 
metabolism101, we have demonstrated that CYP metabolism only accounts for a small 
portion of NDGA’s biological oxidation.  Autoxidation is the main mechanism for 
NDGA oxidation in RLM161.  Previous studies have been performed at biological pH 
and temperature, however considering that the half-life for NDGA in this range is 3.12 
hours; it is possible that the biological effects produced by NDGA may be influenced by 
the o-Q as well.  
Incubations of SECO in RLM in both the presence and absence of GSH indicated 
that SECO underwent conversion to lariciresinol without formation of a stable reactive 
quinone intermediate (submitted data from Chapter 6).  Lariciresinol is formed by 
intramolecular cyclization of the aliphatic hydroxyl group on SECO with the distal 
benzylic carbon. The intramolecular cyclization of SECO to lariciresinol is believed to 
occur sufficiently rapidly, such that it out competes the formation of an intermolecular 
adduction between SECO and GSH.  Secoisolariciresinol may be oxidized to a quinone 
methide intermediate before being converted into lariciresinol although further studies 
would have to be done to confirm this mechanism (Scheme 7.1). 
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Scheme 7.1: Potential reaction scheme for the conversion of secoisolariciresinol (SECO) 
to lariciresinol (Lar) by cytochrome P450 enzymes in rat hepatic microsomes. 
 
 
Objective 2 - Study the autoxidation of Nordihydroguaiaretic acid. 
An HPLC method was developed to allow quantification of an NDGA 
autoxidation product.  The stability of NDGA was investigated by measuring the loss of 
NDGA in aqueous phosphate-citric acid buffer over the range of pH 6.0 to 9.0 at 37ºC.  
A pH rate profile was generated and half-lives were calculated.  NDGA undergoes base 
catalyzed autoxidation at 37ºC with a decreasing half-life with increasing pH level.  The 
half-life of NDGA at physiologically relevant pH 7.4 is 3.12 hours163. 
Our previous studies demonstrated that nordihydroguaiaretic acid (NDGA) 
undergoes autoxidation in aqueous media under physiologically relevant conditions.  
Reports in the literature suggest that NDGA is unstable in aqueous media and that in the 
presence of molecular oxygen that NDGA may be converted to an ortho-quinone (o-Q)31 
or “activated NDGA”121.  We aimed to determine the structurally identity of the NDGA 
autoxidation product in aqueous media. 
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 When GSH was not present in the reaction mixture three products were 
generated.  Two of the products were consistent with quinone formation and the third 
product was consistent with a quinone that had undergone hydroxylation.  
Glutathione addition to the reaction mixture resulted in the disappearance of two 
of the products and subsequent appearance of two NDGA-GSH adducts.  The third non-
GSH reactive oxidation product was determined to be a unique, stable, schisandrin-like 
dibenzocyclooctadiene product that formed as a result of NDGA cyclization. 
Nordihydroguaiaretic acid autoxidation in aqueous media in the presence of 
molecular oxygen leads to the formation of a novel schisandrin-like 
dibenzocyclooctadiene product which has a UV absorption maximum that is consistent 
with previous reports of “activated NDGA”.  NDGA is known to be an inhibitor of 
lipoxygenase184 and CYP enzymes102, experiments which are performed under 
conditions where NDGA can autoxidise to the dibenzocyclooctadiene.  It may be 
possible that the effects previously ascribed to NDGA may actually be the result of o-Q 
intermediate or dibenzocyclooctadiene production. 
Aboriginal preparations of creosote bush involve processes such as boiling the 
leaves for consumption as a tea or processing into a salve.  It is conceivable that the 
preparations generated from creosote bush may contain amounts of NDGA-derived 
dibenzocyclooctadiene which may be responsible for some of the therapeutic effects of 
creosote bush. 
 
Objective 3 - Study the inhibition of CYP isoforms 1A2, 2B, 2C11 and 3A by lignans. 
An HPLC method and a fluorescence plate reader method were optimized to 
separate and quantify metabolites of P450-mediated testosterone and resorufin methyl 
ether metabolism, respectively, which would allow us to assess the inhibition of CYP 
isoforms 1A2, 2B, 2C11 and 3A by lignans. 
In order to gain a better understanding of why the creosote bush lignan, 
nordihydroguaiaretic acid (NDGA) is toxic while flaxseed lignans are safe, we wanted to 
study the ability of lignans to undergo bioactivation in rat hepatic microsomes (RLM).  
We previously determined that NDGA undergoes bioactivation in RLM161 but that 
SECO did not (submitted data, Chapter 6).   
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 To add to our knowledge of how lignan structure can influence inhibition of CYP 
enzymes, we examined a number of lignans that are derived from both creosote bush and 
flaxseed.  The lignans from creosote bush include NDGA and NDGA 
dibenzocyclooctadiene and the flaxseed lignans including secoisolariciresinol 
diglucoside (SDG), SECO, anhydrosecoisolariciresinol (ASECO), and enterodiol (ED) 
and enterolactone (EL), the mammalian lignans derived from SECO. 
None of the lignans examined produced irreversible, mechanism-based inhibition 
of any of the P450 isoforms.  Neither SDG nor ED caused reversible inhibition of the 
P450 examined however ED caused activation of all of the P450 isoforms studies at low 
concentrations.  In addition, SECO, EL and NDGA caused activation of CYP3A and 
2B/2C11 at low concentrations. 
We postulated that the addition of the nucleophile GSH to RLM incubations, 
before the addition of lignan and substrate, would attenuate the inhibition of CYP1A2 by 
NDGA.  GSH had little impact on NDGA inhibition of CYP1A2 activity however at 50 
µM NDGA, GSH attenuated inhibition, and appeared to cause activation of CYP1A2 
(submitted paper, Chapter 6).  
Secoisolariciresinol, ASECO, EL, NDGA and the NDGA dibenzocyclooctadiene 
all caused reversible inhibition of P450 enzyme activity that involved either competitive 
or mixed-type inhibition. The relevance of the inhibition interactions in vivo is likely 
limited though, as the inhibition occurred at lignan concentrations which were greater 
than the anticipated physiologically relevant concentrations.  We concluded that neither 
P450-mediated bioactivation nor reversible inhibition can explain the differences in 
toxicity noted between the lignans of creosote bush and flaxseed.  There was no direct 
relationship between the structures of the lignans and the pattern of P450 inhibition or 
activation. Rather, the ability of NDGA to autoxidise and cause damage to tissues via 
covalent modification or generation of reactive oxygen species seems a more viable 
hypothesis.  
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 7.2 Future Directions 
The novel finding that NDGA autoxidizes to the NDGA dibenzocyclooctadiene 
under physiological in vitro conditions leads to a number of questions.  Is it possible that 
either the o-Q intermediate or the autoxidized NDGA dibenzocyclooctadiene product is 
responsible for some of the activities which are currently associated with NDGA, such 
as lipoxygenase inhibition184?  Could the creosote bush extraction processes used in 
traditional healing preparations lead to the formation of the NDGA 
dibenzocyclooctadiene?  Is the NDGA dibenzocyclooctadiene causing the beneficial 
properties of the creosote bush, or is the NDGA dibenzocyclooctadiene responsible for 
the toxic properties associated with Chaparral consumption?  Studies to investigate the 
lipoxygenase inhibition and chemopreventive properties in addition to the in vitro and 
animal in vivo use of the NDGA dibenzocyclooctadiene are warranted. 
Secoisolariciresinol conversion to lariciresinol did not result in the formation of a 
stable quinone derived GSH adduct.  It is possible that, based on the phenolic structure 
of SECO, that it could be oxidized to a p-QM before being directly converted to 
lariciresinol.  However, further studies both NMR and perhaps electron paramagnetic 
resonance would need to be investigated to validate the process (Scheme 7.1).  
Some of the lignans investigated caused activation of P450 enzymes.  It is not 
clear whether the increase in P450 activity would occur in vivo or not.  In order to 
further study the effect of the lignans on P450 enzymes and downstream consequences 
that this would have, animal dosing studies would be warranted.   
Performing animal studies in rats would allow us to gather further information 
about potential for drug-natural product interactions.  Livers could be analyzed for a 
number of different parameters such as enzyme induction, by measuring mRNA, protein 
levels and activity.  Assessment as to whether any protein adducts have formed within 
the liver could also be measured which would indicate that reactive intermediate 
formation had occurred.  In addition, measuring the levels of catalase and superoxide 
dismutase and levels of GSH and GSH reductase could generate further proof into 
whether oxidative stress is occurring in the liver due to formation of reactive 
intermediates. 
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APPENDIX A – Supplementary figures for “A Comparison Between Lignans From 
Creosote Bush and Flaxseed and Their Potential to Inhibit Cytochrome P450 Enzyme 
Activity” 
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Figure A1: Cytochrome P450 enzyme activity (as percent of control) as a function of 
Secoisolariciresinol diglucoside (SDG) concentration and pre-incubation time. a) 
CYP1A2, b) CYP3A, c) CYP2B/2C11 and d) CYP2C11. Secoisolariciresinol 
diglucoside (closed diamond = 0 µM; closed square = 100 µM; closed triangle = 250 
µM; symbol ‘x’ =  500 µM; open circle = 2000 µM) was pre-incubated in pooled male 
rat hepatic microsomes (n=4) for different time periods. At the end of each pre-
incubation period, testosterone (250 µM) and methoxyresorufin (0.5 µM) was added and 
metabolite formation was determined after a 15 min and 8 min reaction time, 
respectively.  Each point is the mean of 3 replicates ± percent coefficient of variation.
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Figure A2: Cytochrome P450 enzyme activity (as percent of control) as a function of 
Secoisolariciresinol (SECO) concentration and pre-incubation time. a) CYP1A2, b) 
CYP3A, c) CYP2B/2C11 and d) CYP2C11. Secoisolariciresinol (closed diamond = 0 
µM; closed square = 500 µM; closed triangle = 1000 µM; symbol ‘x’ =  1500 µM; open 
circle = 2000 µM) was pre-incubated in pooled male rat hepatic microsomes (n=4) for 
different time periods. At the end of each pre-incubation period, testosterone (250 µM) 
and methoxyresorufin (0.5 µM) was added and metabolite formation was determined 
after a 15 min and 8 min reaction time, respectively.  Each point is the mean of 3 
replicates ± percent coefficient of variation. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 102
 0
20
40
60
80
100
120
0 5 10 15 20
Preincubation Time (min)
%
 o
f C
on
tro
l
a)
0
20
40
60
80
100
120
0 5 10 15 20
Preincubation Time (min)
%
 o
f C
on
tro
l
b)
  
0
20
40
60
80
100
120
0 5 10 15 20
Preincubation TIme (min)
%
 o
f C
on
tro
l
c)
0
20
40
60
80
100
120
0 5 10 15 20
Preincubation Time (min)
%
 o
f C
on
tro
l
d)
 
Figure A3: Cytochrome P450 enzyme activity (as percent of control) as a function of 
Anhydrosecoisolariciresinol (ASECO) concentration and pre-incubation time. a) 
CYP1A2, b) CYP3A, c) CYP2B/2C11 and d) CYP2C11. Anhydrosecoisolariciresinol 
(closed diamond = 0 µM; closed square = 1 µM; closed triangle = 10 µM; symbol ‘x’ =  
50 µM; open circle = 100 µM) was pre-incubated in pooled male rat hepatic microsomes 
(n=4) for different time periods. At the end of each pre-incubation period, testosterone 
(250 µM) and methoxyresorufin (0.5 µM) was added and metabolite formation was 
determined after a 15 min and 8 min reaction time, respectively.  Each point is the mean 
of 3 replicates ± percent coefficient of variation. 
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Figure A4: Cytochrome P450 enzyme activity (as percent of control) as a function of 
Enterolactone (EL) concentration and pre-incubation time. a) CYP1A2, b) CYP3A, c) 
CYP2B/2C11 and d) CYP2C11. Enterolactone (closed diamond = 0 µM; closed square 
= 50 µM; closed triangle = 100 µM; symbol ‘x’ =  250 µM; open circle = 500 µM) was 
pre-incubated in pooled male rat hepatic microsomes (n=4) for different time periods. At 
the end of each pre-incubation period, testosterone (50 µM) and methoxyresorufin (0.5 
µM) was added and metabolite formation was determined after a 15 min and 8 min 
reaction time, respectively.  Each point is the mean of 3 replicates ± percent coefficient 
of variation. 
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Figure A5: Cytochrome P450 enzyme activity (as percent of control) as a function of 
Nordihydroguaiaretic acid (NDGA) concentration and pre-incubation time. a) CYP1A2, 
b) CYP3A, c) CYP2B/2C11 and d) CYP2C11. Nordihydroguaiaretic acid (closed 
diamond = 0 µM; closed square = 1 µM; closed triangle = 10 µM; symbol ‘x’ =  100 
µM; open circle = 200 µM) was pre-incubated in pooled male rat hepatic microsomes 
(n=4) for different time periods. At the end of each pre-incubation period, testosterone 
(250 µM) and methoxyresorufin (0.5 µM) was added and metabolite formation was 
determined after a 15 min and 8 min reaction time, respectively.  Each point is the mean 
of 3 replicates ± percent coefficient of variation. 
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Figure A6: Cytochrome P450 enzyme activity (as percent of control) as a function of 
Dibenzocyclooctadiene concentration and pre-incubation time. a) CYP1A2, b) CYP3A 
and CYP2B/2C11. Dibenzocyclooctadiene (closed diamond = 0 µM; closed square = 25 
µM; closed triangle = 50 µM; symbol ‘x’ =  75 µM; open circle = 100 µM) was pre-
incubated in pooled male rat hepatic microsomes (n=4) for different time periods. At the 
end of each pre-incubation period, testosterone (50 µM) and methoxyresorufin (0.5 µM) 
was added and metabolite formation was determined after a 15 min and 8 min reaction 
time, respectively.  Each point is the mean of 3 replicates ± percent coefficient of 
variation. 
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Figure A7: CYP1A2 enzyme activity (as percent of control) as a function of 
Nordihydroguaiaretic acid (NDGA) concentration in the presence of glutathione 
performed at various pre-incubation times. a) 0 min, b) 5 min, c) 10 min and d) 20 min. 
Nordihydroguaiaretic acid (solid bar) or Nordihydroguaiaretic acid and 500 µM 
glutathione (stipled bar) was pre-incubated in pooled male rat hepatic microsomes (n=4) 
for different time periods. Glutathione was present before initiation of the reaction. At 
the end of each pre-incubation period methoxyresorufin (0.5 µM) was added and 
metabolite formation was determined after an 8 min reaction time. Each point is the 
mean of 3 replicates ± percent coefficient of variation. 
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Figure A8: Nordihydroguaiaretic acid (NDGA) concentration dependent inhibition of 
CYP1A2 in the presence (solid bar) and absence (stipled bar) of 500 µM glutathione 
using methoxyresorufin as the probe substrate in incubation reactions (8 min) with 
pooled (n=4) male, rat liver microsomes. Graphs represent methoxyresorufin 
concentrations of: a) 0.25 µM, b) 0.5 µM, c) 1.0 µM and d) 2.5 µM. Each point 
represents the mean of 3 replicates ± percent coefficient of variation. 
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